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ABSTRACT 
 
 
Generalized  linear   models  with  Poisson  error were  applied to  investigate 
HIV/AIDS relative survival. Relative excess risk of death within 3 years after 
HIV/AIDS   diagnosis    was   significantly   higher   for non-Hispanic blacks, 
American Indians and Hispanics compared with non-Hispanic Whites. Excess 
hazard of death was also higher   among male injection   drug users compared 
with men who have sex   with   men (MSM). The relative excess hazard of old 
HIV/AIDS patients was   significantly higher compared with younger patients 
(e.g., 60+ age  group  versus 19-29 year  age group). When CD4 increased, the  
relative excess hazard decreased; while with the increase of HIV viral load, the  
relative excess   hazard   decreased.   Our population-based results showed that   
viral  load  was  a  determinant  risk  factor  of  disease  progression  after  HIV  
infection; basically  the mean residual life has similar trend to relative survival. 
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CHAPTER 1. INTRODUCTION 
 
 
1. History of HIV Infection 
 
 From late the 1970s to early 1980s in the United States and Europe, the emergence 
of immunologic dysfunction among patients of unknown etiology attracted popular 
attention [1]. Following the unusual occurrence of Pneumocystis carinii pneumonia (PCP) 
in five homosexual men from Los Angeles was reported to the Centers for Disease Control 
and Prevention (CDC) in 1981 [2], several similar reports, describing male homosexuals 
and intravenous drug users with impaired immune systems and T lymphocytes were sent to 
CDC [3]. Because more than 90% of these cases occurred in homosexual or bisexual men, 
the new term “gay-related immunodeficiency” (GRID) was coined.  However, in 1982, 
hundreds of similar cases of AIDS had been reported, not only in homosexual and bisexual 
men, but also in intravenous drug users, hemophiliacs, blood-transfusion recipients, 
heterosexual adults from the Caribbean and Central Africa, sex partners of infected 
patients, and infants born to mothers with the syndrome.  The common symptoms of the 
AIDS patients were due to the depletion of CD4+ T-lymphocyte subset.  
 The similar epidemiological pattern implicated that a new emerging disease was 
transmitted by a novel pathogen in contaminated blood or fluid through sexual intercourse 
and other contact with an affected individual. In AIDS patients, the presence of 
lymphadenopathy in many affected individuals was reminiscent of the clinical course 
related to human viral pathogens, the attention was focused on viruses to infect cells of the 
immune system. Several candidate viruses were isolated, including cytomegaloviruses 
(CMVs), and human T-cell leukemia virus type-I (HTLV-I) [4]. In 1983, scientists at the 
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Pasteur Institute discovered a virus from the lymph nodes of an asymptomatic individual; 
the scientists presented their discovery with Gallo and colleagues at the National Institutes 
of Health [5]. Subsequently Gallo reported the isolation of retroviruses from AIDS patients, 
which they named HTLV-III. In 1994 Levy et al reported a similar retrovirus isolated from 
both AIDS patients and healthy individuals from the various risk groups [6] which they 
named the AIDS-associated retrovirus (ARV). The new retrovirus, associated with AIDS 
in the United States, Europe, and central Africa and exhibiting typical morphologic and 
genetic characteristics of the Lentivirus genus, was named human immunodeficiency virus 
(HIV) [7], and subsequently HIV-1. In 1986, a related, but immunologically distinct and 
less pathogenic human retrovirus (now called HIV-2), was recovered from individuals 
residing in several Western African countries [8]. 
 
 
2. Epidemiology 
 
 
 The HIV pandemic is one of the most notorious infectious disease epidemics in 
human history. Its morbidity and mortality rates are staggering. In 2001, there were 36 
million HIV-infected individuals worldwide [9]. In 2005, it was estimated that 38.6 (range 
35~46) million people worldwide were living with HIV.  More than 21.8 million deaths 
have been due to HIV infection since the beginning of the epidemic [9]. In 2005 alone, 
3.4~4.2 million people died of AIDS and nearly 4.1 (range 3.4~6.2) million individuals 
worldwide acquired HIV infection [9]. There were an estimated 925,000-1,025,000 
persons living with HIV/AIDS at the end of 2003 in the US., and approximately 40,000 
new HIV infections occur each year [10].  HIV is transmitted by:  
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• mucosa contact (oral, rectal, or vaginal)during sex; 
• transfusion of HIV contaminated blood products, use of contaminated equipment ; and   
• maternal-fetal circulation or by breast feeding.  
 Sexual transmission accounts for more than 90% of HIV infections worldwide [10]. 
Transmission of HIV is dependent on behavioral and biologic factors. The probability of 
male-to-female HIV transmission during vaginal sex is approximately 0.1% to 0.2% per 
contact; receptive anal intercourse is associated with a considerably higher risk (0.82/per 
contact ) of HIV transmission [11]. Risk factors (variables) associated with transmission 
included the genetic background of the host, the size of the injured mucosa, and the local 
environment in which the exposure occurs.  
 With the advent of highly active antiretroviral therapy (HAART), the morbidity 
and mortality rates of HIV infection are decreasing dramatically in Europe and the USA 
[12]. However, in some of Africa and Asian countries, HIV morbidity and mortality rates 
are increasing due to the ineffective implementation of prevention and intervention policies 
[13]. 
 
3. Clinical Manifestation 
 
 
 Usually, HIV infection includes a long period (approximately 10 years) of clinical 
latency between the time of primary infection and the development of symptoms indicative 
of advanced immunodeficiency. The clinical symptoms of HIV infection were evolved on 
the depletion of CD4+ T-cell lymphocytes and the replication of HIV RNA.  In the acute 
and early stages of the disease, there are some “flu-like” and “mononucleosis-like” 
illnesses, such as fever, rash, pharyngitis, and “lymphadenopathysis-like” illnesses.  
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Additionally, myalgias, arthralgias, diarrhea, nausea, vomiting, headache, 
hepatosplenomegaly, weight loss, thrush, and neurological symptoms may appear. For 
patients developing symptoms during primary HIV infection, the mean duration of 
symptoms is 3 weeks [14]. 
 
 When CD4+ T-cell count falls below 500 cells/uL, the following symptoms can be 
observed: oropharyngeal, recurrent vulvovaginal candidiasis, bacillary angiomatosis 
(usually due to infection with Bartonella henselae), recurrent or multidermatomal herpes 
zoster, listeriosis, infections due to Rhodococcus equi, pelvic inflammatory disease, oral 
hairy leukoplakiaassociated with EBV, cervical dysplasia (usually associated with human 
papillomavirus infection), constitutional symptoms such as unexplained fever or diarrhea 
lasting more than 1 month, idiopathic thrombocytopenic purpura, and peripheral 
neuropathy.  
 
 In late stage of HIV infection, when CD4+ T-cell count is below the level of 
approximately 200 cells/uL, cellular immune responses are tremendously suppressed. 
Which cause many opportunistic infections, such as chronic microsporidiosis, 
gastrointestinal infection with Cyclospora cayetanensis, disseminated Penicillium 
marneffei infection (endemic to southeast Asia), cerebral or disseminated Trypanosoma 
cruzi infection (endemic to Latin America), relapsing or chronic visceral leishmaniasis, 
anal carcinoma, and EBV-positive cases of leiosarcoma, leiomyosarcoma, and Hodgkin's 
disease. The increased risk in developing AIDS-defining illnesses associated with a CD4+ 
T-cell count of less than 200 cells/uL led to the 1993 revision of the CDC definition of 
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AIDS, which includes a low CD4+ T-cell count (<200 cells/uL) as an AIDS-defining 
criterion [15]. 
 
4. Biology  
 Human immunodeficiency virus (HIV) is a member of the retrovirus family in the 
retroviridae (1). HIV is a genetically diverse population of viruses that is responsible for 
causing AIDS in much of West Africa (referred to as HIV- 2), and causing AIDS 
throughout the rest of the world referenced as HIV-1 (1).    
 Based on the nucleotide acid sequence of complete viral genomes, HIV-1 was 
subsequently defined and classified into three groups: M (major), O (outlier), and N (non-
M or O).  The M group of HIV-1, which includes over 95% of the global virus isolates, 
consists of at least eight discrete clades A, B, C, D, F, G, H, and J (see the maximum 
likelihood tree in   Figure 1). 
 The first step for HIV to infect a target cell is to bind the HIV receptor and 
coreceptors expressed on the surface of the target cells (such as T help lymphocytes, which 
are called as CD4+ T-helper/inducer subset of lymphocytes, abbreviated as CD4+ T-cells 
or CD4). Consequently, the main cellular targets for HIV-1 are the CD4+ T-helper/inducer 
subset of lymphocytes, CD4+ cells of macrophage lineage, and some populations of 
dendritic cells. 
 In order to quantitatively measure the amount of HIV in serum of HIV-infected 
patients, many technologies were developed, the commonly recognized method was 
polymerase chain reaction (PCR), the copy number of HIV RNA per micro liter serum 
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could be used as a rapid and sensitive measure of viral load, the copy number of HIV RNA 
in serum was often referred as HIV viral load [16]. 
 
 HIV infection can cause the selective depletion of CD4+ cells, therefore, CD4+ T- 
cell count and HIV viral load are two of the most important variables to predict the 
clinical prognosis of HIV-infected subjects. 
5.   Laboratory Diagnosis  
 The specific biomarkers (antigen and antibodies) of HIV infection can be captured 
by serologic tests. Commonly, Enzyme-Linked ImmunoSorbent Assay (ELISA) was the 
preliminary screening test for HIV infection. Because ELISA often generates some false 
positive results,  a positive ELISA test must always be followed by a confirmatory Western 
blot assay [17].  The ideal diagnosis marker of HIV infection should be easily and 
reproducibly measurable in all individuals with the disease. Furthermore, it should worsen 
with progression of disease and improve with positive responses to therapy.  
 CD4+ T cell count is the “Marker of Immune System Dysfunction” [18]. CD4+ T 
cells are the primary targets of HIV infection. Depletion of CD4+ T cells is the 
immunologic hallmark of HIV disease progression. Measurement of CD4+ T cells should 
be an excellent marker of disease progression.  Some investigations have demonstrated that 
the CD4+ T-cell count is a powerful predictor of the short-term risk of developing an 
AIDS-defining illness [19]. CD4+ T-cell counts frequently increase in response to 
antiretroviral therapy, and this salutary response has been used as a criterion in the 
licensing of new anti-HIV drugs. A number of other indicators of immune dysregulation 
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correlate with HIV disease progression. The percentage of peripheral blood CD8+ T cells 
bearing the activation marker CD38 is positively correlated with disease progression [20].  
 
 Measurement of the CD4+ T-cell count yields information regarding the degree of 
immunodeficiency; quantification of HIV RNA in plasma obtains the information related 
to the rate and severity of immune deficiency. Technology currently available for 
reproducible measurement of plasma viremia in clinical specimens includes PCR, RT-PCR, 
nucleic acid sequence–based amplification (NASBA), and branched DNA (b-DNA) assays. 
The plasma viremia level of more than 100,000 HIV RNA copies/mL at 6 months after 
seroconversion was associated with an odds ratio of 10.8 for the development of AIDS.   
The level of plasma viremia at 7 to 12 months after seroconversion was a strong predictor 
of CD4+ T-cell depletion during follow-up [1, 19]. 
 Current recommendations regarding the initiation and maintenance of antiretroviral 
therapy rely heavily on the two best laboratory markers for HIV disease progression, the 
CD4+ T-cell count and the HIV viral load [21-22]. 
 
6. Treatment and Prevention  
 
 Highly active antiretroviral therapy (HAART), a single or combination of several 
drugs, has high activity to inhibit HIV RNA replication. HIV cocktail therapy is a 
combination reagent, which inhibits the replication of HIV RNA at different steps of HIV 
life-cycling.   The currently available HIV inhibition reagents can be categorized into 
reverse transcriptase inhibitors, protease inhibitors, and integrated zinc-finger inhibitors. 
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Inhibitors of viral reverse transcriptase (RT) like zidovudine and lamivudine were the first 
agents to be developed for the treatment of HIV infection. The protease inhibitors, such as 
saquinavir, ritonavir, indinavir, nelfinavir, amprenavir, and lopinavir, are all potent 
antiretrovirals, particularly when used in combination with nucleoside analog RT inhibitors 
(NRTIs) [23]. 
 Adherence to an antiretroviral treatment is a complex issue since antiretroviral 
regimens are multiple agents, and must be taken indefinitely in most cases. Many of the 
drugs have intolerable side effects and toxicities (nausea, vomiting, and/or diarrhea).  
Lapses in adherence provide the opportunity for virus replication, and enhance the 
probability of the emergence of drug-resistant virus mutants. Another insurmountable 
challenge for therapy is the presence of an HIV latent reservoir in resting CD4+ memory T 
cells [24]. 
 
 A treatment regimen should be selected that will afford a high likelihood of long-
term profound suppression of plasma viral load and a significant increase in the CD4+ T-
cell count. Currently, the most useful prophylaxis strategy for HIV infection is to stop the 
virus transmission:  condom use, blood screening, and preventing mother to child 
transmission.   
 An effective weapon in preventing further spread of the HIV epidemic will be a 
safe and effective vaccine. Even though tremendous efforts have been made and several 
promising candidate vaccines have been generated,   there are huge unknown puzzles that 
remain to be elucidated in this field.        
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7.   Statistical Advances and Challenges in HIV/AIDS Modeling  
Many statistical methodologies have been developed for modeling the HIV epidemic [25, 
26], new therapies (HAART), prophylaxis strategies [27, 28],   and HIV incidence [29-32]. 
Many of challenges remain to be elucidated by collaborative efforts from mathematicians 
, biologists and epidemiologists. For the treatment of HIV infection, the common 
philosophy is: “treat early and treat hard” [22, 23].  Because HIV genetic divergent 
mutants emerge constantly, the corresponding treatment and prevention methods need to 
be created accordingly. Therefore, it is indispensable to develop and identify optimal 
treatment strategies for HIV-infected individuals.  How to determine an optimal treatment 
regimen is a great challenge. At present, there are a large number of treatment options, 
statisticians need to help clinicians figure out the following questions: 
 What is the best initial treatment combination? 
 When is the best time for a certain patient to switch from one regimen to another? 
 What multi-drug treatment sequence generates the best treatment effect? 
  
 Another statistical challenge is to estimate the efficacy of intended treatment. Since 
many potential treatment strategies become available, the reported promising new dugs 
may coincide with relevant clinical trials in progress. Thus, the patients may be attracted to 
withdraw from the trials to which they are party. The investigators may change the initial 
protocol to reflect the new achievement. Under this circumstance, the intend-to-treat rule 
may not generate unbiased estimation [33]. 
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The most commonly used bio-markers, CD4+ T-cell count and viral load, are subject to 
high variability during disease progression. It is necessary to measure them repeatedly over 
time for each patient. The treatment efficacy on the marker progress can be estimated by a 
standard multivariate model or mixed model.  CD4+ T cell count and HIV viral load often 
have missing values due to the death of patients or loss of follow up.  Several non-
parametric methods have been developed for solving the missing data problem [34, 35].      
 
8. HIV/AIDS relative survival and mean residual life analysis   
Conventionally, net or crude survival was employed to analyze and predict patients’ 
clinical disease progression after diagnosis. Recently, relative survival has become a very 
popular survival analysis method for cancer patients [36-38].  The prerequisite for net or 
cause-specific survival analysis is that fact of death information should be available. For 
HIV infected patients, it will generate some confusion when net survival is selected to 
extrapolate the survival of HIV-infected patients. According to the CDC 1993 definition, 
factors other than HIV infection can cause death of AIDS patients. HIV-infected patients 
have different opportunistic infections (OIs) as well as divergent co-infection (HBV, HCV, 
CMV, HPV, HSV). It is not a rare event that causes other than HIV infection will appear in 
the death certificates of AIDS patients. Therefore, it is more realistic to use relative 
survival to model and analyze disease progression of HIV/AIDS patients [38, 39]. For 
HIV/AIDS patients,  relative survival is estimated as the ratio of observed survival of the 
HIV/AIDS patients (where all deaths are considered as events) to the expected survival of 
the general population,  matched to the patients with respect to the main factors (age, race, 
sex, calendar year ) and assumed to be free of  HIV infection.       
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Mean residual life is a measurement of the remaining life expectancy of a subject at time t, 
which is the remaining survival time given the subject surviving up to t.  It has been widely 
applied to many fields [40].  
Since relative survival analysis can be used to identify the determinant factors of 
HIV/AIDS clinical progression, it has been taken as a reliable approach to estimate the 
efficacy of prophylaxis and treatment strategies of HIV-infected subjects. However, 
inconsistent results have been reported from different cohort studies. The inconsistency 
was related to the divergence of sample size, follow up time periods and the failure to 
correct important co-founding variables. In this study, we will conduct systematic and 
comprehensive relative survival and mean residual life analyses of HIV/AIDS patients 
with the most recent data from the United State National HIV/AIDS reporting system 
(HARS). 
In chapter II, we describe the methods for data analysis. Chapter III includes data analysis 
and results.  Chapter VI contains the discussion.  Chapter V includes conclusions for this 
study.  Chapters VI, VII, VIII, and IX are references, tables, figures, and appendixes 
respectively.       
                                 
CHAPTER II.  METHODS 
 
 
1.  Data Source   
1.1. Definitions 
 HIV-infected patients (HIV): For most HIV-infected patients, HIV infection 
time is unknown. The HIV patient’s diagnosis information in HARS is the date of first 
HIV positive test  (HIV seroconversion time). The primary screening test of HIV 
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infections is called as Enzyme-Linked ImmunoSorbent Assay (ELISA). The confirming 
test of HIV infection is Western blot. After the positive ELISA test of HIV 
antigen/antibody, if the Western blot test is also positive, then the patient is considered 
HIV infected.  
 AIDS patients (AIDS):  According to the CDC case definition, one has AIDS if 
he/she is infected with HIV and presents with one of the following:  
(1) A CD4+ T-cell count below 200 cells/µl (or a CD4+ T-cell percentage of total 
lymphocytes of less than 14%), or    
(2) He/she has one of the common defining opportunity illnesses [15]. 
1.2. Datasets Used in the Study 
 Data of 1996-2003 diagnosed AIDS patients were from the U.S. national HARS, 
including all 50 United States; 1996-2003 diagnosed HIV cases were  from 25 states 
(Alabama, Arizona, Arkansas, Colorado, Idaho, Indiana, Louisiana, Michigan, Minnesota, 
Mississippi, Missouri, Nevada, New Jersey, North Carolina, North Dakota, Ohio, 
Oklahoma, South Carolina, South Dakota, Tennessee, Utah, Virginia, West Virginia, 
Wisconsin, and Wyoming).   Data used in this study satisfy the following criteria: 
 
• Inclusion criteria: 
(1) AIDS patients were from the HARS.AS_JUN06 dataset: N = 976,105 
observations, 614 variables. 
(2) Laboratory data from the LAB.RA_JUN06 dataset: N= 1,418,260 
observations  ,351 variables.                  
(3) HIV patients from the HARS.HS_JUN06 dataset: N= 266,437 observations, 
613 variables. 
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• Exclusion criteria: 
(1) HIV/AIDS patients diagnosed at age <13 years. 
(2) HIV infection diagnosis year or month was missing. 
(3) AIDS diagnosis year or month was missing. 
(4) HIV/AIDS patients’ death year or month was missing. 
(5) HIV/AIDS diagnosis year was <1996 or > 2003. 
• Follow up:  patients were followed up through the end of 2005.  The maximum follow 
up time was 10 years.   
The observed survival probabilities of AIDS patients were calculated by using the Kaplan-
Meier method for the corresponding datasets. The expected survival probability was 
obtained by merging the national population data and mortality datasets sorted by age, sex, 
race/ethnicity, and calendar year. Both the population denominators and numerator 
mortality rate were from the National Center for Health Statistics [41]. The death rate in 
2005 was not available and was therefore assigned to be the same value as that in 2004 in 
the analysis. The maximum age in the mortality dataset was 85 years. So if a person’s age  
in the population dataset is over 85 years, his\her age will be assigned as  85 years. 
2. Models and Estimation Approaches of Relative Survival and Mean Residual Life   
2.1. Models of Relative Survival  
 For HIV/AIDS patient with covariate vector z, the hazard rate at time t is modeled 
as the sum of the expected hazard rateλ*(t; z) and the excess hazard rate v(t; z) due to a 
diagnosis of AIDS:  
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     λ( t; z )   =   λ*(t; z)  +    v(t;  z) ,                                                 (1) 
where the expected hazard (sometimes called the baseline hazard) is estimated from 
general-population mortality rates. 
  The corresponding survival function can be written as:  
 
 S(t; z)  =   S*(t; z)  r(t; z),   or   r(t; z) =  S(t; z) / S*(t; z ),       (2) 
 
Where r(t; z) is the relative survival. 
 If the excess hazard rate, v(t; z), is assumed to be a multiplicative function of the 
covariates, written as exp(z’β), then the model for the relative survival of patients with 
HIV/AIDS diagnosis is : 
 λ (t; z) = λ*(t; z)  +  exp(z’β ),      (3) 
 
where β is an unknown parametric vector. Based on the equation (3), estimation methods 
of relative survival were developed in references [42-44] with full likelihood and 
generalized linear model (GLM) approaches.   
 
2.2. Estimation Approaches of Relative Survival Analysis   [45] 
     Four approaches can be applied to estimate the relative survival with the dataset of 
AIDS to death (339,863 AIDS patients, diagnosed from 1996 to 2003, followed up through 
the end of 2005): 
(1) Grouped survival times, GLM with a binomial error structure ; 
(2) Grouped survival times, GLM with a Poisson error structure ; 
(3) Exact survival times, individual subject-band observations;  
(4) Exact survival times, collapsed data, GLM with a Poisson error structure.  
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  The collapsed data used in the fourth approach contained the same number of 
observations as the grouped data sets. The distinction between collapsed data and grouped 
data is that, in the collapsed data, y (person time, years at risk using exact times yi) and 
d* (d* expected death number) are based on the exact time at risk whereas these 
quantities are approximated for grouped data. 
 The selected models were fitted with AIDS patient data and the general-population 
mortality rates. The excess hazard ratios, or relative excess risks, are assumed to be an 
exponential function of unknown parameters [46]. An excess hazard ratio of, for example, 
1.5 for a patient with HIV viral load 2 unit,  compared to a patient with HIV viral load 1 
unit  means that the excess risk of  death  will increase 50% if the HIV RNA copy number 
in peripheral blood increases 1 unit.    
 
2.3 Relative excess hazard ratio and AIDS free survival proportion  
 
Model (4) was used to estimate the main effect for each variable adjusted for all of the 
other variables in the model. The first level of each variable was set up as reference level. 
After obtaining the main effect of each level, the relative excess hazard ratio was the 
exponentiated rate of the effect for the corresponding level to the referenced level.  AIDS 
free survival proportion was calculated using the Kaplan Meier method.                     
 
2.4 Modeling and Estimation of HIV/AIDS Mean Residual Life 
Mean residual life is a measurement of the remaining life expectancy of a subject at time t, 
which is the remaining survival time given the subject surviving up to t. Dr. Qin and Dr. 
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Zhao’s methodology was employed to model the distribution of HIV/AIDS mean residual 
life [40].     
 3. Variable Selection and Model Checking 
 The AIDS to death cohort dataset was used for model building. The dataset has 
976105 observations, 614 variables, plus the variables (CD4+ T cell count, HIV viral load 
as well as CD4+ T-cell count detection times) from the laboratory dataset; the total variable 
count was 663. Based on published papers [22, 38], sex, age group, race, transmission 
category, HIV/AIDS diagnosis year, CD4+ T-cell count, viral load were selected for 
inclusion in our model. These variables have a close relationship with disease development 
and clinical progression. In our dataset, the HIV viral load has a large amount of missing 
(57.3%); CD4+ T-cell count information has 14.2% missing (see the discussion).  
 The selected approaches (see table 5 for detail) (1), (2) and (4) are generalized 
linear models. They can be checked by the deviance statistic which is a measure of 
goodness-of-fit [43]. Excess hazard in approaches (1), (2), and (4) require the assumption 
of proportional hazard in a pre-specified interval band, so each variable will be tested using 
the log rank test.    
          All the analyses were implemented using SAS 9.1 program, except that the analysis 
of HIV/AIDS means residual life was performed using S-plus version 7.0. 
 
CHAPTER III.  DATA ANALYSIS AND RESULTS 
 
 Three datasets were generated: 339,863 AIDS cases were selected for the study of 
AIDS to death; for the HIV sero-conversion (HIV) to death study, 122,391 HIV-infected 
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patients were selected; for the HIV sero-conversion (HIV) to AIDS study, 122,379 HIV-
infected patients were selected. 
   
1. Variable selection and survival curve analysis 
 The log rank test was used to check the significance of seven preliminary selected 
variables: race/ethnicity (non-Hispanic white (white), non-Hispanic black (black), Hispanic, 
Asian/Pacific Islander (A/PI), and American Indian/Alaska Native (AI/AN)), age at 
diagnosis, sex (male and female), diagnosis year, HIV transmission category (men who 
have sex with men(MSM), male drug user, female drug user,  men sex men and drug user, 
female  high risk heterosexual contact, male high risk heterosexual contact, CD4+ T-cell 
count,  and HIV viral load. 
For variable selection, survival curves were plotted by each risk factor to check 
equality over strata for the proportional hazard assumption. Figure 2 shows that Blacks and 
AI/AN had worse survival probabilities compared with A/PI. Figure 3 shows that there is 
an obvious monotonous trend among the age groups. The survival probability of AIDS 
patients decreases when age increases. Figure 4 shows that the survival probabilities from 
highest to lowest transmission categories are: male to male sex (MMS, similar to MSM), 
female high-risk heterosexual contact (HCF), male high-risk heterosexual contact (HCM), 
unknown risk group, MSM and injection drug use (IDU), male injection drug use (IDUM), 
female injection drug use (IDUF). Injection drug users are the highest risk AIDS 
transmission group. Additionally, from Figure 4, the assumption of proportional hazard 
was not valid for the variable transmission category. After adding interaction terms (MSM 
with IDU, HCM vs HCF), the assumption of proportional hazard was valid.  From Figure 5, 
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we observe that patient survival was better when AIDS was diagnosed later in time (e.g., 
2003 versus 1996).  Figure 6 shows that the survival curves of males and females are very 
similar.   Figure 7 indicates that the survival probability of AIDS patients would improve 
with increased CD4+ T-cell count (first CD4+ T-cell count within 6 months of AIDS 
diagnosis). Figure 8 shows that with the increased viral load (first available record), the 
survival probability among AIDS diagnosed patients decreased.          
 
2. Relative survival from AIDS diagnosis to death  
 Table 1 provides the results of relative survival probabilities from AIDS diagnosis 
to death.  There were 339,863 persons diagnosed with AIDS at age >= 13 years in the 50 
states and the District of Columbia from 1996 to 2003.  Forty eight percent of the AIDS 
patients were black, 31% were white, 20% were Hispanic, and less than 1% were A/PI or 
AI/AN (Table 1, columns 2, 3). The number of male AIDS patients was 3 times the 
number of females. Seventy two percent of patients were from 30 to 50 years old.  Twenty 
seven percent were diagnosed with AIDS at very low CD4+ T-cell counts (<50 cells/uL). 
 Hispanic and Black AIDS patients have lower relative survival probability 
compared with white patients. AI/ANs have the lowest relative survival probability.  
Generally, with the increase of age at AIDS diagnosis and viral load, the relative survival 
rate among AIDS-diagnosed patients decreases; while with increasing CD4+ T-cell count  
in peripheral blood, the relative survival probability increases.   
 
 The difference of the cumulative relative survival probability between men and 
women was small; women had slightly higher survival at one year and slightly worse at 
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three years after AIDS diagnosis compared with men. One and three years after AIDS 
diagnosis, MSM had the highest cumulative relative survival probability compared with all 
the other transmission categories. Injection drug users had the worst relative survival 
probability.   From 1996 to 2003, each year the survival of newly diagnosed AIDS patients 
was slightly better, even though year to year improvements were not significant.      
 
3. Relative survival from HIV infection diagnosis to death 
  
           Table 2 gives the results from HIV diagnosis to death for cases diagnosed from 
1996 to 2003 in 25 states using integrated HIV/AIDS surveillance reporting system. Fifty 
percent of HIV patients were black, 34% were white, 8.5% were Hispanic, and less than 
1% was Asian/Pacific Islander or American Indian/Alaska Native (Table 2, columns 2, 3). 
The number of males was almost 3 times the number of female HIV patients (males 
account for 72%, females 28%). Over sixty percent of HIV patients were aged from 30-49 
years; twenty three percent were 20-29 years old. Sixteen percent were diagnosed with 
HIV at very low CD4+ T-cell conut (<50 cells/uL). 
 The differences of the cumulative relative survival rates among race/ethnicity, sex 
and diagnosis year can be seen in Table 2 (column 4 for 1-year and column 6 for 3-year 
cumulative survival). Similar to AIDS, HIV patients diagnosed at older ages had lower 
relative survival rates compared with those diagnosed at younger ages. Among different 
transmission categories, the injection drug users had the lowest relative survival. HIV 
infected patients with higher CD4+ T-cell count also had better survival, but this 
information was missing for 25% of patients. If the HIV patients had lower viral loads, 
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they would have higher relative survival. Fifty one percent of patients did not have viral 
load test results.     
 
4. Relative excess hazard ratio 
 
 Table 3 presents the results obtained by using the estimation approach (4). Columns 
2 and 4 present the relative excess hazard rate for AIDS and HIV patients respectively. The 
excess hazard rate of death for black, Hispanic, and AI/AN with AIDS and HIV patients 
were investigated after adjustment for sex, age, transmission category, diagnosis year, 
CD4+ T-cell count as well as HIV viral load. For each category, the first level was used as 
the reference level. For race, HIV infected AI/AN patients have the highest relative excess 
hazard rate (1.41 and 1.37 for AIDS and HIV, respectively). A/PI AIDS cases had the 
lowest relative excess hazard rate (0.95 and 0.91 for AIDS and HIV, respectively). In 
contrast to the corresponding circumstance in relative survival analysis, the relative excess 
hazard rates of AIDS to death and HIV to death increased with the increase of age at AIDS 
diagnosis. If HIV viral load increased, then the relative hazard rate for AIDS and HIV 
patients increased; while with increasing CD4+ T-cell  count, the relative excess hazard 
rates decreased. From 1996 to 2003, each year the relative excess hazard rate of newly 
diagnosed AIDS and HIV decreased slightly. For certain variables (such as race/ethnicity), 
compared with HIV, all the AIDS patients had higher relative excess hazard rate except 
age group. The relative excess hazard rate for the oldest 60+ year AIDS patients was 6.93 
(95% CI: 5.94 to 8.09); while for HIV patients, it was 20.14 (95% CI:  14.5 to 28.1).    
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5. AIDS free survival proportion from HIV to AIDS diagnosis 
 
 From Table 4, we can see that among 122,379 patients diagnosed with HIV from 
1996 to 2003, 64,423 progressed to AIDS before the end of 2003.  Among 2003 HIV 
diagnoses, after 12 months, 60% of the patients had not progressed to AIDS; after 36 
months, 56% had not developed AIDS. Sixty percent of women had not progressed to 
AIDS 3 year after HIV diagnosis; while 50% HIV infected males had developed AIDS 
during that time frame. 
 HIV infected A/PIs were least likely to have developed AIDS 3 years after HIV 
diagnosis compared with Blacks, Hispanics, or American Indians/Alaska Natives. The 
AIDS-free rate of patients diagnosed with HIV at younger ages was higher compared with 
those diagnosed with HIV infection at older ages for both 1 and 3 year after HIV diagnosis. 
Among transmission categories that affect both men and women, the AIDS-free survival 
rate at 36 months was higher for women than for men. The AIDS-free survival rate did not 
change substantially between diagnosis year, but did improve from 1996 to 2003 (50.0 to 
55.9 for 3 years after HIV diagnosis). AIDS-free survival probability decreased with 
increasing HIV viral load, when HIV viral load was up to 5, the AIDS-free survival 
probability decreased dramatically.        
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6. Model comparison and model checking    
 Table 5 shows that the main effect for each variable had no obvious difference 
when estimated by different models (the values of main effect are similar for a single 
variable from different models). Model 1 was developed based on equation 9. Assuming 
that the number of deaths in each interval follows a binomial distribution, the outcome is 
kiki dl −  (the number of patients surviving the interval), with binomial error structure with 
denominator kil .  Model 2 was built based on grouped events (deaths) with approximate 
survival time. The number of deaths in a pre-specified time interval band (length = 1 year) 
follows a Poisson distribution with approximate survival time. Model 3 was developed 
based on the assumption that the number of deaths in a pre-specified interval band (length 
= 1 year) follows a Poisson distribution, but the data are individual level and survival time 
is the exact time.  Model 4 was generated from the assumption that the number of deaths in 
a pre-specified interval band (length = 1 year) follows a Poisson distribution, the data are 
from grouped level and survival time is exact.  The goodness of fit test for selected 
approaches has p a value greater than 0.05, so there is not enough evidence to reject the 
current models, thus our data fit the models well.   
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CHAPTER 4.  DISCUSSION 
 
       HIV infection prevention is one of the most challenging tasks for public health 
workers. In order to improve the quality of life of HIV-infected patients and extend the 
interval from HIV infection /AIDS diagnosis to death, the US Department of Health and 
Human Services has implemented the use of many prophylaxis, intervention strategies and 
methodologies, such as mass media campaigns, peer education about HIV transmission, 
treatment of other sex transmitted infection, condom social marketing, safe blood provision, 
and needle exchange. Survival analysis is not only a conventional technology but also a 
frequently implemented technique to evaluate the efficiency of new treatment and 
prevention methods. Relative survival was a very popular cancer survival analysis 
technique; the first advantage is that   it does not need the information of the specific cause 
of death.  Another advantage is that relative survival analysis excludes the effect of 
baseline mortality (such as old age) on the survival rate under study [47, 48]. Compared 
with cancer studies, this population-based survival analysis recently began to attract the 
attention of HIV/AIDS researchers [37, 38]. HIV/AIDS relative survival analysis will 
provide a measure of the excess mortality experienced by patients diagnosed with HIV 
infection or AIDS, irrespective of whether or not the excess mortality is directly or 
indirectly attributable to HIV infection. 
        Our results showed that the relative excess hazard of death was higher for blacks, 
American Indian /Alaska Natives, as well as Hispanics with HIV infection and AIDS 
diagnosis as compared with whites. Excess risk for death also was higher for persons with 
a diagnosis of HIV or AIDS at an older age, and lower CD4+ T-cell count at diagnosis. 
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Additionally, if HIV/AIDS patients have a higher viral load, they will have a higher 
relative excess hazard rate compared to the HIV/ AIDS patients, who have a lower HIV 
viral load.       
        CD4+ T-cell count is one of the most commonly used surrogates for disease 
progression [49, 50] and disease severity/immune dysfunction as well as a criterion for 
evaluation of the effect of clinical and prophylaxis intervention applied in HIV/AIDS 
patients. Usually, the variable data on this marker is characterized by unequal numbers of 
unevenly spaced repeated observations. In our data set, a patient can maximally have up to 
20 times CD4+ T-cell count values. Almost half of patients have no CD4+ T-cell count 
information (48%) (the time interval between any two time CD4+ T-cell count values is 
different for each patient). CD4+ T-cell count has many components of variability: 
measurement error, short term variability, and long term trend. To avoid the correlation 
among repeated CD4+ T-cell count in one subject, we used the first CD4+ T-cell count in 
our model after disease diagnosis but within 6 months of HIV infection or AIDS diagnosis. 
Further investigation is needed to determine the effect of the missing data of CD4+ T-cell 
count on results.  Since 1996, using HIV viral load as an independent predictor variable to 
predict outcome (disease progression, treatment) has attracted wide attention [1, 51].  The 
results from our study are similar to previous publications:  the higher HIV RNA viral load, 
the lower survival probability [1, 51].  
        Similar results were obtained from our analysis and other research about the effect of 
diagnosis age for HIV/AIDS as an important determinant of disease progression. Our 
results show that younger patients have the advantage of surviving longer than older 
patients. It was reported that younger age favored CD4+ T-cell restoration upon HAART, 
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which is consistent with younger persons having good thymic function for CD4+ T-cell 
generation [1].  With respect to the transmission categories, IDUs had lower relative 
survival probability (higher relative hazard rate) 36 months after HIV infection and AIDS 
diagnosis than other transmission categories. Independent of HIV infection, IDU patients 
have an increased risk of death from overdose, violent causes, HCV co-infection, liver 
toxicity, or a decline of adherence of treatment [38].  All of these risk factors might 
contribute to this transmission category pattern. Between men and women, there was no 
significant difference in relative excess risk for death and the relative survival. 
        The disparities of the AIDS-free survival probability in our analysis may relate to 
access or adherence to treatment or diagnosis delay, or lack of adequate care. If AIDS 
diagnosis is delayed in disadvantaged population groups (e.g., Hispanics), then it is 
difficult to obtain a precise estimate of the AIDS-free probability difference (between 
Hispanics, blacks, and whites) if it exists.  
        The advantage of relative survival analysis is obvious for HIV/AIDS survival studies. 
In the cohort dataset of HIV to death, it was found that 15% of HIV patients were dead 
before AIDS diagnosis. These patients were not dead from AIDS defining events; secondly, 
we do not need the cause-specific information of death, which can be biased toward under 
ascertainment of HIV/AIDS as a cause of death, to perform relative survival analysis. 
         For model selection, generalizability depends on independent predictors.  Our model 
included the most important progress factors so far identified. From the point of model 
simplicity, we did not include genetic factors (MIDR1, 3435C/T polymorphism, CCR5)32 
mutation), which have been shown to affect response to antiretroviral therapy [52].  
Consideration of the specificity of survival data (events may count at pre-specified 
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intervals or at the exact survival time), four approaches were tested to model the relative 
excess hazard of death by using the AIDS to death cohort dataset. Similar results for 
estimating the relative survival were obtained when using different models.  This is not 
surprising since similar methods and datasets were used to model the relative survival of 
AIDS patients. Model (1) was based on a binomial assumption. Model (2) used grouped 
data (events were counted in approximate survival time).  Model (3) used individual level 
of data.  Finally, model (4) used collapsed events obtained from exact survival time.    
        The relative survival results of Table 1, 2 and 3 were obtained with the generalized 
linear model (model 4) based on collapsed data with exact survival times and a Poisson 
assumption. The resulting Goodness of fit test showed that our data fit well for the selected 
model 4, with a deviance/df of  0.7799.  Meanwhile, two term interactions were tested.  It 
was found that there were significant interactions between age and year of follow-up (fu), 
age and diagnosis year (dxyr). The main effects of follow-up year and sex are not 
significant in the model, thus, they should be excluded from the final model. The final 
model may include age, race/ethnicity, transmission category, CD4+ T-cell count, viral 
load, and the two interactions fuXage and fuXdxyr.     
        The approach developed by Qin and Zhao [40] was used to estimate the mean residual 
life for HIV and AIDS patients after survival 12 months after diagnosis. Our results 
showed that the estimated mean residual life for HIV and AIDS patients followed the same 
pattern as the survival probability: if the HIV and AIDS patient groups had a higher 
relative survival probability (or survival probability), then they had a longer mean residual 
life (white patients); if the patients had a lower survival probability (injection drug users), 
then they had a shorter mean residual life. Compared to the results of survival probability, 
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the mean residual life was shorter than expected, especially for newly diagnosed HIV and 
AIDS patients. This bias may be associated with the large amount of censoring and the 
dependency between censoring and survival time.  More than 80% of AIDS cases 
diagnosed in 2003 were censored.  A case with a longer survival time has a higher 
probability of being censored. Therefore, the results on mean residual life were not shown. 
We will continue our efforts to solve this problem in estimating the mean residual life.  
        Survival analysis is a widely accepted method to evaluate the efficacy of new 
treatment and prophylaxis strategies. In our study, the nation-wide HIV/AIDS data was 
used to estimate the mean residual life. Mean residual life has the potential to be easily 
understood by clinicians. For example, at the time point (t) to implement a new treatment 
or a new HIV vaccine (after HIV/AIDS patients surviving 12 months), the mean residual 
life is the improved life time of HIV and AIDS patients after using the new treatment or 
the new vaccine.  
        Since only the first time detection data of CD4+ T-cell count and viral load was 
included in the model (both CD4+ T-cell count and viral load can be used to reflect disease 
stage or severity).  One of the limitations in our study was that we did not have information 
on the severity of the HIV infection caused disease. Furthermore, over 50% of the viral 
load information was unknown. Secondly, for most patients, HIV infection time was 
unknown, we used HIV seroconversion time to replace HIV infection time, which may 
cause a slight difference in the survival analysis from HIV infection to AIDS/death. Finally, 
The data used to assess relative survival among persons with an HIV diagnosis (with or 
without a concurrent diagnosis with AIDS) or assess disease progression from HIV 
 28
diagnosis to AIDS included 25 states; and it is not known whether results can be 
extrapolated to the United States as a whole. 
        Further efforts are needed to address whether differences in survival and mean 
residual life are the result of treatment and/or prevention interventions.  CD4+ T-cell count 
obtained at different time points need to be incorporated in models describing the full 
scenario of disease progression. HIV viral load as an independent variable to predict 
survival and mean residual life deserves further investigation. 
 
Chapter  5.  CONCLUSIONS 
• Generalized linear model with Poisson error structure was an appropriate approach for 
estimating the relative survival of HIV/AIDS patients. 
• Younger persons, MSM, and whites have better survival compared to older, IDUs,   
blacks, and Hispanics after HIV or AIDS diagnosis.  
• HIV diagnosed patients have higher relative excess hazard compared with AIDS 
diagnosed patients. 
• When viral load was larger than log5, the AIDS-free survival probability 36 months 
after HIV diagnosis decreased considerably.             
• HIV viral load is a very important risk factor affecting HIV/AIDS survival (its value of 
the estimated main effect and the relative excess hazard is highest).   
• It is worthwhile to further the analysis of mean residual life for HIV/AIDS patients.   
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                      Table 1 Relative survival after AIDS diagnosed from 1996 to 2003, 
                                                                  by 50 US States 
 
Characteristics  Frequency Percent
    
CR1   CICR1 CR3    CICR3 
Race/ethnicity       
  non-Hispanic white 104104 30.6 88.8 (88.5, 88.9) 81.0 (80.7, 81.3) 
  non-Hispanic black 163154 48.0 86.6 (86.4, 86.7) 75.2 (75.0, 75.5) 
  Hispanic 68196 20.1 86.4 (86.2, 86.7) 78.6 (78.3, 79.0) 
  Asian/Pacific Islander 3063 0.9 88.0 (86.8, 89.1) 82.8 (81.3, 84.2) 
  American Indian/Alaska Native 1346 0.4 85.4 (83.3, 87.1) 73.2 (70.3, 75.9) 
Age at diagnosis (years)       
  13-19 2728 0.8 96.2 (95.4, 96.8) 89.6 (87.6, 91.3) 
  20-29 43386 12.8 92.2 (92.0, 92.5) 83.8 (83.3, 84.2) 
  30-39 137193 40.4 90.0 (89.8, 90.1) 81.2 (80.9, 81.4) 
  40-49 107259 31.6 85.8 (85.7, 86.1) 76.0 (75.7, 76.3) 
  50-59 36574 10.8 80.2 (79.8, 80.7) 70.0 (69.4, 70.4) 
  60+ 12723 3.7 69.2 (68.3, 70.0) 59.2 (58.2, 60.1) 
Transmission category       
  MSM 120762 35.5 89.8 (89.6, 90.0) 82.8 (82.5, 83.0) 
  IDU Male 50866 15.0 83.4 (83.0, 83.7) 70.4 (70.0, 70.9) 
  IDU Female 23648 7.0 86.2 (85.8, 86.6) 71.0 (70.3, 71.7) 
  MSM+IDU 18010 5.3 90.8 (90.3, 91.2) 79.8 (79.0, 80.4) 
  HC Male 40054 11.8 81.4 (80.9, 81.7) 73.2 (72.8, 73.8) 
  HC Female 20359 6.0 85.2 (84.7, 85.7) 76.0 (75.3, 76.6) 
  Unknown 66164 19.5 89.0 (88.8, 89.3) 79.6 (79.2, 79.9) 
Sex       
  Male 255371 75.1 87.0 (86.9, 87.2) 78.2 (78.0, 78.4) 
  Female 84492 24.9 87.8 (87.5, 87.9) 76.4 (76.1, 76.8) 
Diagnosis year       
  1996 58286 17.2 84.2 (84.0, 84.6) 71.8 (71.4, 72.2) 
  1997 47637 14.0 86.8 (86.4, 87.0) 75.4 (75.0, 75.9) 
  1998 40932 12.0 86.6 (86.2, 86.9) 76.2 (75.8, 76.7) 
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  1999 39067 11.5 87.2 (86.8, 87.5) 77.4 (76.9, 77.9) 
  2000 39392 11.6 87.8 (87.4, 88.1) 78.4 (77.9, 78.8) 
  2001 38210 11.2 88.2 (87.9, 88.6) 79.6 (79.2, 80.1) 
  2002 38073 11.2 88.8 (88.5, 89.1) 81.4 (81.0, 81.9) 
  2003 38266 11.3 90.0 (89.6, 90.3) 86.0 (85.5, 86.3) 
First CD4 CNT       
  <50 91730 27.0 81.0 (80.8, 81.3) 69.0 (68.7, 69.4) 
  50-99 43815 12.9 88.2 (87.9, 88.5) 77.8 (77.4, 78.3) 
  100-199 96745 28.5 93.6 (93.4, 93.8) 85.4 (85.1, 85.7) 
  >=200 59497 17.5 93.8 (93.5, 93.9) 86.8 (86.4, 87.1) 
  Unknown 48076 14.2 77.2 (76.8, 77.6) 67.8 (67.3, 68.2) 
Log10(viraload)       
  1-2 14052 4.1 98.8 (98.6, 99.1) 96.8 (96.4, 97.3) 
  3 23872 7.0 97.6 (97.3, 97.8) 94.0 (93.6, 94.4) 
  4 30966 9.1 96.4 (96.2, 96.6) 91.0 (90.6, 91.4) 
  5 53801 15.8 93.8 (93.7, 94.1) 86.0 (85.6, 86.3) 
  6-8 22321 6.6 89.8 (89.5, 90.3) 79.8 (79.1, 80.4) 
  Unknown 194851 57.3 81.4 (81.3, 81.7) 69.8 (69.6, 70.1) 
Total 339863 100.00 87.2 (87.1, 87.3) 77.8 (77.6, 77.9) 
 
 
CR1:     1-year cumulative relative survival proportion.  
CICR1: 95% confidence interval of 1 –year cumulative survival rate.  
CR3:     3-year cumulative relative survival proportion.  
CICR3: 95% confidence interval of 3 –year cumulative survival rate.  
MSM:  men who have sex with men.  
MSM+IDU: men who have sex with men and injection drug user;  
HC:  heterosexual contact with a person at high-risk for or a person with HIV infection or AIDS;  
AIDS:  acquired immunodeficiency syndrome; HIV:  human immunodeficiency virus. 
First CD4 CNT: First CD4+ T cell count within 6 months of AIDS diagnosis.   
Viraload:  HIV RNA copy number.   
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                       Table 2 Relative survival after HIV diagnosis from 1996 to 2003,  
                                                      by 25 US States  
 
Characteristics  Frequency Percent 
  
CR1   CICR1 
 
CR3  CICR3 
Race/ethnicity       
  non-Hispanic white 42120 34.4 93.4 (93.1, 93.6) 89.2 (88.9, 89.6) 
  Non-Hispanic Black 68386 55.9 93.4 (93.1, 93.5) 87.2 (87.0, 87.6) 
  Hispanic 10358 8.5 93.2 (92.7, 93.7) 89.2 (88.4, 89.8) 
  Asian/Pacific Islander 636 0.5 93.6 (91.5, 95.3) 91.6 (89.1, 93.7) 
  American Indian/Alaska Native 891 0.7 92.2 (90.1, 93.7) 85.6 (82.6, 88.1) 
Age at diagnosis( years)       
  13-19 3822 3.1 99.4 (99.0, 99.5) 98.2 (97.3, 98.9) 
  20-29 27824 22.7 97.8 (97.7, 98.0) 95.2 (94.9, 95.5) 
  30-39 46412 37.9 94.6 (94.4, 94.9) 90.2 (89.8, 90.5) 
  40-49 31021 25.4 91.0 (90.6, 91.3) 84.6 (84.1, 85.0) 
  50-59 9949 8.1 85.8 (85.0, 86.4) 77.8 (76.9, 78.7) 
  60+ 3363 2.8 73.4 (71.9, 75.0) 64.6 (62.6, 66.4) 
Transmission category       
  MSM 43745 35.7 94.6 (94.4, 94.9) 90.6 (90.3, 91.0) 
  IDU Male 10859 8.9 89.8 (89.2, 90.4) 80.6 (79.6, 81.4) 
  IDU Female 5276 4.3 92.8 (92.1, 93.6) 84.4 (83.1, 85.5) 
  MSM+IDU 4248 3.5 95.0 (94.3, 95.7) 88.6 (87.3, 89.6) 
  HC Male 8756 7.2 94.6 (94.1, 95.1) 89.2 (88.5, 90.1) 
  HC Female 16315 13.3 96.4 (96.0, 96.6) 92.0 (91.5, 92.5) 
  Unknown 33192 27.1 90.6 (90.4, 91.0) 85.6 (85.2, 86.1) 
Sex       
  Male 88578 72.4 92.8 (92.6, 93.0) 87.6 (87.4, 87.9) 
  Female 33813 27.6 94.6 (94.4, 94.9) 89.4 (89.1, 89.8) 
Diagnosis year       
  1996 17716 14.5 92.0 (91.6, 92.4) 84.8 (84.1, 85.4) 
  1997 16569 13.5 93.2 (92.9, 93.6) 86.8 (86.2, 87.4) 
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  1998 15229 12.4 92.8 (92.4, 93.2) 87.2 (86.5, 87.7) 
  1999 14324 11.7 93.2 (92.7, 93.5) 87.6 (86.9, 88.2) 
  2000 14924 12.2 93.6 (93.3, 94.1) 88.6 (88.0, 89.2) 
  2001 14543 11.9 93.6 (93.2, 94.0) 88.6 (88.0, 89.2) 
  2002 14862 12.1 94.0 (93.6, 94.4) 90.4 (89.8, 91.0) 
  2003 14224 11.6 94.2 (93.7, 94.5) 92.4 (91.9, 92.9) 
First CD4 CNT       
  <50 20443 16.7 83.0 (82.4, 83.4) 71.8 (71.0, 72.4) 
  50-99 8628 7.1 90.0 (89.3, 90.6) 82.0 (81.0, 82.9) 
  100-199 15289 12.5 94.8 (94.4, 95.2) 88.0 (87.4, 88.7) 
  >=200 45366 37.1 98.8 (98.6, 98.8) 96.4 (96.1, 96.5) 
  Unknown 32665 26.7 92.4 (92.1, 92.7) 88.8 (88.4, 89.2) 
Log10(viraload)       
  1-2 3571 2.9 99.4 (99.0, 99.7) 97.8 (97.1, 98.5) 
  3 10754 8.8 99.2 (98.9, 99.3) 97.2 (96.7, 97.6) 
  4 16299 13.3 98.8 (98.5, 98.9) 96.4 (96.0, 96.8) 
  5 21238 17.4 96.0 (95.8, 96.4) 90.8 (90.3, 91.2) 
  6-8 7840 6.4 90.6 (89.8, 91.1) 82.4 (81.3, 83.3) 
  Unknown 62689 51.2 90.0 (89.7, 90.2) 83.8 (83.4, 84.1) 
Total 122391 100.0 93.4 (93.2, 93.4) 88.2 (87.9, 88.3) 
 
CR1:     1-year cumulative relative survival proportion.  
CICR1: 95% confidence interval of 1 –year cumulative survival rate.  
CR3:     3-year cumulative relative survival proportion.  
CICR3: 95% confidence interval of 3 –year cumulative survival rate.  
MSM:  men who have sex with men.  
MSM+IDU: men who have sex with men and injection drug user;  
HC:  heterosexual contact with a person at high-risk for or a person with HIV infection or AIDS;  
AIDS:  acquired immunodeficiency syndrome; HIV:  human immunodeficiency virus. 
First CD4 CNT: First CD4+ T cell count within 6 months of AIDS diagnosis.   
Viraload:  HIV RNA copy number.   
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                Tables 3 Relative excess hazard rate of death within 3 years among   
                        patients with HIV or AIDS diagnosed from 1996 to 2003 
 
  AIDS       patients       HIV infection patients* 
Characteristics 
          
RR** AIDS RR 95% CI 
             
RR** HIV RR 95% CI 
Race/ethnicity     
  non-Hispanic white 1.00  1.00  
  non-Hispanic black 1.15 (1.13, 1.17) 1.02 (0.98, 1.07) 
  Hispanic 1.18 (1.15, 1.21) 1.07 (1.00, 1.15) 
  Asian/Pacific Islander 0.95 (0.86, 1.04) 0.91 (0.69, 1.21) 
  American Indian/Alaska Native 1.41 (1.26, 1.59) 1.37 (1.12, 1.67) 
Age at diagnosis (years)     
  13-19 1.00  1.00  
  20-29 2.00 (1.71, 2.33) 2.55 (1.83, 3.55) 
  30-39 2.43 (2.09, 2.83) 4.81 (3.47, 6.68) 
  40-49 3.26 (2.80, 3.80) 7.19 (5.19, 9.98) 
  50-59 4.53 (3.89, 5.28) 11.17 (8.04, 15.5) 
  60+ 6.93 (5.94, 8.09) 20.14 (14.5, 28.1) 
Transmission category     
  MSM 1.00  1.00  
  IDU Male 1.51 (1.48, 1.55) 1.55 (1.46, 1.65) 
  IDU Female 1.65 (1.58, 1.74) 1.73 (1.55, 1.94) 
  MSM+IDU 1.08 (1.04, 1.13) 1.14 (1.02, 1.27) 
  HC Male 1.01 (0.98, 1.05) 0.83 (0.76, 0.90) 
  HC Female 1.15 (1.10, 1.20) 0.97 (0.88, 1.07) 
  Unknown 1.54 (1.50, 1.58) 1.37 (1.30, 1.44) 
Sex     
  Male 1.00  1.00  
  Female 0.98 (0.95, 1.02) 0.92 (0.86, 0.98) 
Diagnosis year     
  1996 1.00  1.00  
  1997 0.86 (0.84, 0.89) 0.89 (0.83, 0.95) 
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  1998 0.86 (0.84, 0.88) 0.87 (0.82, 0.93) 
  1999 0.84 (0.81, 0.86) 0.84 (0.78, 0.90) 
  2000 0.86 (0.83, 0.88) 0.79 (0.74, 0.85) 
  2001 0.83 (0.81, 0.86) 0.82 (0.76, 0.88) 
  2002 0.77 (0.75, 0.80) 0.69 (0.64, 0.74) 
  2003 0.69 (0.66, 0.71) 0.66 (0.61, 0.71) 
First CD4 CNT     
  <50 1.00  1.00  
  50-99 0.64 (0.62, 0.65) 0.57 (0.54, 0.61) 
  100-199 0.38 (0.38, 0.39) 0.36 (0.34, 0.39) 
  >=200 0.40 (0.39, 0.41) 0.13 (0.12, 0.14) 
  Unknown 0.92 (0.90, 0.94) 0.35 (0.34, 0.37) 
Log10(viraload)     
  1-2 1.00  1.00  
  3 2.24 (1.92, 2.62) 1.79 (1.20, 2.69) 
  4 3.83 (3.31, 4.44) 2.80 (1.90, 4.12) 
  5 6.01 (5.21, 6.93) 5.11 (3.51, 7.43) 
  6-8 8.49 (7.35, 9.80) 7.84 (5.39, 11.4) 
  Unknown 13.87 (12.1, 16.0) 10.49 (7.24, 15.2) 
 
 
*HIV infection diagnosed with or without a concurrent diagnosis of AIDS 
**Relative excess hazard rate adjusted for all other variables (follow up period result not shown)   
MSM:  men who have sex with men; IDU:  injection drug user;  
MSMIDU: men who have sex with men and IDU: injection drug user;  
HC:  heterosexual contact with a person at high-risk for or a person with HIV infection or AIDS;  
AIDS:  acquired immunodeficiency syndrome; HIV: human immunodeficiency virus. 
First CD4 CNT: First CD4+ T cell count within 6 months of AIDS diagnosis.   
Viraload:  HIV RNA copy number.   
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 Table 4   AIDS free survival proportion from HIV to AIDS diagnosed  
                                    from 1996 to 2003, by 25 US States  
 
 
Characteristics  Frequency Percent       P1     CIP1    P3     CIP3 
Race/ethnicity        
  Non-Hispanic white 42120 34.4 58.3 (57.8, 58.7) 51.6 (51.1, 52.1) 
  Non-Hispanic black 68373 55.9 62.6 (62.3, 63.0) 53.29 (52.9, 53.7) 
  Hispanic 10360 8.5 55.0 (54.0, 56.0) 47.5 (46.5, 48.5) 
  Asian/Pacific Islander 636 0.5 58.3 (54.4, 62.1) 51.8 (47.6, 55.9) 
  American Indian/Alaska Native 890 0.7 60.9 (57.6, 64.0) 51.6 (48.0, 55.1) 
Age at diagnosis (years)       
  13-19 3822 3.1 86.7 (85.5, 87.7) 77.0 (75.4, 78.5) 
  20-29 27822 22.7 75.6 (75.1, 76.1) 66.8 (66.1, 67.4) 
  30-39 46397 37.9 59.2 (58.8, 59.7) 51.0 (50.4, 51.4) 
  40-49 31023 25.4 52.3 (51.8, 52.9) 44.2 (43.6, 44.8) 
  50-59 9947 8.1 46.2 (45.2, 47.1) 39.1 (38.1, 40.2) 
  60+ 3368 2.8 39.2 (37.6, 40.9) 33.9 (32.2, 35.6) 
Transmission category       
  MSM 43744 35.7 57.7 (57.2, 58.1) 49.8 (49.3, 50.3) 
  IDU Male 10856 8.9 52.4 (51.5, 53.3) 42.8 (41.8, 43.8) 
  IDU Female 5273 4.3 65.9 (64.6, 67.2) 55.0 (53.4, 56.4) 
  MSM IDU 4245 3.47 60.9 (59.4, 62.3) 50.0 (48.2, 51.5) 
  HC Male 20971 17.1 59.0 (58.3, 59.7) 52.3 (51.6, 53.0) 
  HC Female 12222 10.0 68.3 (67.4, 69.1) 61.1 (60.2, 62.0) 
  Unknown 25068 20.5 64.9 (64.3, 65.4) 55.8 (55.1, 56.5) 
Sex       
  Male 88572 72.4 57.5 (57.2, 57.8) 49.4 (49.0, 49.7) 
  Female 33807 27.6 68.2 (67.7, 68.6) 59.6 (59.0, 60.2) 
HIV diagnosis year       
  1996 17708 14.5 58.7 (57.9, 59.4) 50.0 (49.2, 50.8) 
  1997 16564 13.5 59.8 (59.1, 60.5) 51.6 (50.8, 52.5) 
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  1998 15227 12.4 59.7 (58.9, 60.5) 51.6 (50.8, 52.5) 
  1999 14324 11.7 60.6 (59.8, 61.4) 52.2 (51.3, 53.1) 
  2000 14923 12.2 60.6 (59.8, 61.3) 51.7 (50.8, 52.5) 
  2001 14545 11.9 61.7 (60.9, 62.5) 52.3 (51.4, 53.2) 
  2002 14862 12.1 61.7 (60.9, 62.4) 53.1 (52.2, 54.0) 
  2003 14226 11.6 61.3 (60.4, 62.0) 55.9 (55.0, 56.7) 
Log10(viraload)       
   1-2 3570 2.9 60.5 (58.9, 62.1) 53.3 (51.6, 55.1) 
   3 10750 8.8 69.2 (68.4, 70.1) 61.6 (60.6, 62.6) 
   4 16297 13.3 72.5 (71.8, 73.2) 62.2 (61.3, 63.0) 
   5 21232 17.4 51.2 (50.5, 51.9) 38.5 (37.8, 39.2) 
   6-8 7841 6.4 29.5 (28.5, 30.5) 19.1 (18.2, 20.1) 
Unknown 62689 51.23 62.8 (62.4, 63.2) 56.8 (56.4, 57.2) 
Total 122379 100 60.4 (60.2, 60.7) 52.2 (51.9, 52.5) 
 
 
P1:      Percentage of 1 year AIDS free survival proportion after HIV diagnosis. 
CIP1:  95% confidence interval of P1. 
P3:      Percentage of 3 year AIDS free survival proportion after HIV diagnosis. 
CIP3:  95% confidence interval of P3. 
MSM:  men who have sex with men.  
HC:  heterosexual contact with a person at high-risk for or a person with HIV infection or AIDS;  
MSM+IDU: men who have sex with men and injection drug user. 
AIDS:  acquired immunodeficiency syndrome; HIV:  human immunodeficiency virus. 
First CD4 CNT: First CD4+ T cell count within 6 months of AIDS diagnosis.   
Viraload: HIV RNA copy number.   
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                                                       Table 5.   Model comparison ( Estimated  excess hazard ratio) 
 
     Model1   Model2         Model3            Model4    
Time    Grouped   grouped         exacted             Exacted 
Distribution     Bin.*   Poi.*  Poi.*, Individual  Poi.*, collapsed  
Df.*    7.60E+04                                      7.60E+04                      9.10E+05   7.60E+04   
Deviance 56179.50   54500   4.84E+05   5.91E+04   
Value/Df*. 0.74   0.719   5.30E-01   7.80E-01   
Parameter        RER low_rer hi_rer        rer low_rer hi_rer               Rer low_rer hi_rer                  rer low_rer hi_rer 
Sex             
  Male         1.0              
  Female 0.99 0.95 1.03 0.99 0.96 1.03 0.98 0.95 1.02 0.98 0.95 1.02 
Age at diagnosis             
  13-19         1.0               
  20-29 1.95 1.67 2.28 1.96 1.68 2.29 1.86 1.59 2.19 2.00 1.71 2.33 
  30-39 2.36 2.03 2.75 2.37 2.04 2.77 2.27 1.94 2.65 2.43 2.09 2.83 
  40-49 3.14 2.70 3.65 3.15 2.70 3.67 3.04 2.60 3.56 3.26 2.80 3.80 
  50-59 4.27 3.67 4.98 4.24 3.63 4.95 4.22 3.60 4.94 4.53 3.89 5.28 
  60+ 6.27 5.37 7.31 6.00 5.14 7.02 6.42 5.48 7.53 6.93 5.94 8.09 
Race/ethnicity             
  white           1.0             
  Black 1.16 1.13 1.18 1.15 1.13 1.17 1.15 1.13 1.18 1.15 1.13 1.17 
  Hispanic 1.16 1.13 1.19 1.16 1.13 1.18 1.18 1.15 1.21 1.18 1.15 1.21 
  Asian 0.94 0.86 1.03 0.94 0.86 1.03 0.95 0.87 1.04 0.95 0.86 1.04 
  Indian 1.41 1.26 1.58 1.37 1.22 1.55 1.42 1.26 1.59 1.41 1.26 1.59 
Transmission  category             
  MSM          1.0             
  IDU Male 1.50 1.46 1.54 1.50 1.46 1.53 1.51 1.48 1.55 1.51 1.48 1.55 
  IDU Female 1.63 1.56 1.71 1.62 1.55 1.70 1.65 1.57 1.73 1.65 1.58 1.74 
  MSM+IDU 1.10 1.05 1.14 1.09 1.05 1.13 1.08 1.04 1.13 1.08 1.04 1.13 
  HC Male 1.01 0.98 1.05 1.01 0.98 1.05 1.01 0.97 1.04 1.01 0.98 1.05 
  HC Female 1.14 1.09 1.19 1.14 1.08 1.19 1.15 1.09 1.20 1.15 1.10 1.20 
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  Unknown 1.49 1.45 1.53 1.48 1.44 1.52 1.54 1.50 1.58 1.54 1.5 1.58 
Diagnosis year             
  1996         1.0            
  1997 0.87 0.84 0.89 0.87 0.85 0.89 0.86 0.84 0.89 0.86 0.84 0.89 
  1998 0.86 0.84 0.89 0.86 0.84 0.89 0.86 0.83 0.88 0.86 0.84 0.88 
  1999 0.84 0.81 0.86 0.84 0.82 0.86 0.84 0.81 0.86 0.84 0.81 0.86 
  2000 0.86 0.83 0.88 0.86 0.84 0.89 0.86 0.83 0.88 0.86 0.83 0.88 
  2001 0.83 0.81 0.86 0.83 0.81 0.86 0.83 0.81 0.86 0.83 0.81 0.86 
  2002 0.78 0.75 0.80 0.78 0.76 0.80 0.77 0.75 0.80 0.77 0.75 0.80 
  2003 0.64 0.62 0.66 0.64 0.62 0.67 0.69 0.66 0.71 0.69 0.66 0.71 
First CD4 CNT            
  <50            1.0            
  50-99 0.65 0.64 0.67 0.65 0.64 0.67 0.64 0.62 0.65 0.64 0.62 0.65 
  100-199 0.40 0.39 0.41 0.40 0.39 0.41 0.38 0.37 0.39 0.38 0.38 0.39 
  >=200 0.42 0.41 0.43 0.42 0.40 0.43 0.40 0.39 0.41 0.40 0.39 0.41 
  Unknown 0.90 0.88 0.92 0.90 0.88 0.92 0.92 0.90 0.94 0.92 0.90 0.94 
Log10(viraload)            
  1-2            1.0            
  3 2.16 1.86 2.50 2.29 1.96 2.69 2.28 1.95 2.67 2.24 1.92 2.62 
  4 3.61 3.14 4.15 3.88 3.34 4.51 3.90 3.36 4.53 3.83 3.31 4.44 
  5 5.57 4.87 6.36 6.05 5.24 7.00 6.13 5.30 7.08 6.01 5.21 6.93 
  6-8 7.78 6.79 8.90 8.44 7.29 9.76 8.66 7.48 10.02 8.49 7.35 9.80 
Unknown 12.34 10.82 14.07 13.45 11.66 15.50 14.16 12.28 16.33 13.87 12.10 16.00 
 
* Bin.: Binomial; Poi.: Poisson; Df.: Degree of freedom.    
RER: relative excess hazard ratio; low_rer: low limit of 95% confidence of RER; hi_rer: upper limit of 95% confidence interval.   
HC:  heterosexual contact with a person at high-risk for or a person with HIV infection or AIDS;  
MSM+IDU: MSM and IDU;AIDS: acquired immunodeficiency syndrome; HIV: human immunodeficiency virus. 
First CD4 CNT: First CD4+ T cell count within 6 months of AIDS diagnosis.   
Viraload:  HIV RNA copy number.   
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Figure-1.  This maximum likelihood tree of HIV 
 
based on full-length pol gene sequences analysis, Phylogenetic relationships of 
HIV-1 groups M, N, and O with four different SIVcpz isolates.  
 
(This picture was from the text book: “Fields Virology, Chapter 60” )  
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                 Figure-2.  Survival after AIDS Diagnosis by Race 
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Figure-3. Survival after AIDS Diagnosis by Age Group (years) 
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Figure-4. Survival after AIDS Diagnosis by Transmission Category 
 
MSM = men who have sex with men; IDU = injection drug user. 
MSM+IDU= men who have sex with men and injection drug user. 
HC = heterosexual contact with a high-risk individual person with HIV infection or 
AIDS;  
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Figure-5. Survival after AIDS Diagnosis by Diagnosis Year 
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Figure-6. Survival after AIDS Diagnosis by Sex 
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Figure-7. Survival after AIDS Diagnosis by CD4+ T Cell Count  
  
(Note: CD4 count was obtained within 6 months after AIDS diagnosis) 
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Figure-8 Survival after AIDS Diagnosis by Viral Load 
 
Note: The number is Log10 (Viral load); >50% observations had missing value for 
viral load. 
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 APPENDICES 
 
Appendix A                                 Abbreviation  
     
 
AIDS                     acquired immune deficiency syndrome 
CD4                       CD4 molecular positive T lymphocyte 
CDC                      Centers for Disease Control and Prevention 
CI                           Cnfidence interval 
CMV                      cytomegaloviruses     
GLM                      generalized linear model        
HAART                  highly active antiretroviral therapy 
HARS                     HIV/AIDS reporting system  
HC                          high-risk heterosexual contact 
HCF                        female high-risk heterosexual contact 
HCM                       male high-risk heterosexual contact 
HCV                        hepatitis C virus    
HIV                         human immunodeficiency virus 
IDU                         injection drug user 
IDUM                      male injection drug user   
IDUF                       female injection drug user    
MSM                       men who have sex with men 
MSM+IDU              men who have sex with men and inject drugs  
RSR                          relative survival rate  
RR                            relative (excess) hazard ratio  
Viraload                   HIV RNA copy number 
RER                         Relative excess hazard ratio 
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Appendix B                 SAS  and S-plus codes  
 
1, SAS code:  AIDS to death relative survival analysis ( for table1 ) 
         
Note: the main difference of  SAS codes for table 2, 3, 5 is the dataset, so I omitted 
the SAS codes for tables 3, 5                     
 
First, to get the AIDS patients dataset, then get the population and mortality dataset 
and  the laboratory dataset. Finally obtain the cohort dataset by merging the 
following datasets :    
• National AIDS  patients,  
• National population data    
• National mortality data,   
• Laboratory data of HARS                
 
1.1 SAS codes to obtain the AIDS data   
 
options nodate nonumber nocenter ps=65 ls=120; 
 
%let dsmth=JUN06;   /* data set month and year */ 
%let startyr=1996;  /* beginning AIDS dx year */ 
%let enddxyr=2003;    /* ending AIDS dx year */ 
%let endfupyr=2005;    /* ending follow-up year */ 
%let maxfupyr=3;    /* maximum follow-up years */run; 
 
title1 "AIDS dx from &startyr to & endyr, reported to CDC as of 
&dsmth"; 
 
data aids; set hars.as_&dsmth(keep = rep_st stateno race sex 
adxyrmo adthyrmo ageaids _amode new_race race_w race_b race_i 
race_p race_a hisp); 
  if ageaids>=13; 
 
  dxyr=int(adxyrmo/100); 
  if &startyr<=dxyr<=&enddxyr; 
  dxmo=mod(adxyrmo,100); 
  /* remove cases with missing months of diagnosis */ 
  if dxmo in (0,.) then delete; 
 
  dthyr=int(adthyrmo/100); 
  dthmo=mod(adthyrmo,100); 
  /* remove cases with missing months of death */ 
  if (dthyr ne .) and ((dthmo in (.,0)) or (adthyrmo<adxyrmo)) then      
  delete; 
 
  if dthyr ne . and dthyr<=&endfupyr  
  then do; death='1'; survmo=(dthyr*12+dthmo)-(dxyr*12+dxmo); end; 
  else do; death='0'; survmo=(&endfupyr*12+12)-(dxyr*12+dxmo); end; 
 
*****mapping new race back to old race***; 
length old_race $1; 
old_race=' '; 
if new_race = '1' then old_race = '3'; 
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  else if new_race = '2' then old_race = '5'; 
  else if new_race in ('3','5','7') then old_race = '4'; 
  else if new_race = '4' then old_race = '2'; 
  else if new_race = '6' then old_race = '1'; 
  else if new_race = '8' then    do; 
      if (race_a = '1' and race_p = '1') and not (race_w = '1' or 
race_b = '1' or race_i = '1' or race in('1', '2', '3', '5')) then 
old_race = '4'; 
      else old_race = '9';    end; 
  else old_race='9'; 
  format old_race $SURRACE. ; 
*******************************************************************
*******; 
  if old_race in('1','2','3','4','5'); 
 
 if _amode = '01' then mode = '1';       /*reclassify risk group*/ 
  else if _amode = '02' then mode = '2'; 
  else if _amode = '03' then mode = '3'; 
  else if _amode = '05' then mode = '5'; 
  else mode='9'; 
 
  if sex in('1','2'); 
 
  keep rep_st stateno dxyr dxmo dthyr dthmo death survmo sex 
old_race mode ageaids; run; 
proc freq data=aids;  
  tables dxyr dxmo dthyr dthmo death survmo sex old_race mode 
ageaids;   run; 
 
 
1.2 SAS codes to obtain population and mortality data 
 
 
/*get the mortality dataset*/ 
 
libname mort '\\cdc\project\DHAP_HICSB_Store1\NCHS MORTALITY 
DATA\DthCertData\XUCyyyy'; run;  
 
%macro mort(year=); 
proc freq data=mort.Xuc&year; 
  tables year*sex*old_race*age/out=out&year missing noprint; 
  run; 
%mend; 
 
%mort(year=1996); 
%mort(year=1997); 
%mort(year=1998); 
%mort(year=1999); 
%mort(year=2000); 
%mort(year=2001); 
%mort(year=2002); 
%mort(year=2003); 
%mort(year=2004); 
 
data mort; set out1996 out1997 out1998 out1999 out2000 out2001 
out2002 out2003 out2004; 
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  death=count; 
  keep year sex old_race age death;  run; 
 
 
 
/*get the population data */ 
%macro pop(range=,year=); 
proc freq data=census.cty_&range; 
  tables sex*old_race*age/out=out&year missing noprint; 
  weight pop&year; 
  run; 
%mend; 
 
%pop(range=9099,year=96); 
%pop(range=9099,year=97); 
%pop(range=9099,year=98); 
%pop(range=9099,year=99); 
 
%pop(range=0005,year=00); 
%pop(range=0005,year=01); 
%pop(range=0005,year=02); 
%pop(range=0005,year=03); 
%pop(range=0005,year=04); 
%pop(range=0005,year=05); 
 
data pop; set out96(in=y96) out97(in=y97) out98(in=y98) 
out99(in=y99) out00(in=y00)  
              out01(in=y01) out02(in=y02) out03(in=y03) 
out04(in=y04) out05(in=y05); 
  pop=count; 
  if y96 then year='1996'; else 
  if y97 then year='1997'; else 
  if y98 then year='1998'; else 
  if y99 then year='1999'; else 
  if y00 then year='2000'; else 
  if y01 then year='2001'; else 
  if y02 then year='2002'; else 
  if y03 then year='2003'; else 
  if y04 then year='2004'; else 
  if y05 then year='2005';  
  keep year sex old_race age pop;  run; 
 
title 'National population by year, sex, old_race, and age'; 
 
proc freq data=pop; 
  tables year sex old_race age/missing; 
  weight pop;  run; 
 
Merge the population and mortality data  
 
 
data mort2005; set mort; 
  if year='2004'; 
  year='2005'; 
run; 
data mort; set n.mort mort2005; 
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  if old_race='9' then delete; 
  if age>85 then age=85; 
proc means noprint data=mort; by year sex old_race age; 
  var death; 
  output out=mort85 sum=death; 
 
data prob; merge n.pop mort85; by year sex old_race age; 
  if age>=13; 
  _year=1*year; 
  _age=age; 
  prob=1-death/pop; 
  keep _year sex old_race _age prob;  run; 
      
 
After obtaining the AIDS, population , mortality , laboratory data, merging 
them    
 
/*get the aids dataset*/ 
data one ; 
set a.aids ; by rep_st stateno ; 
run; 
 
proc contents data= one; run; 
 
/*get the laboratory dataset */ 
data two ; 
set HIV.lab2; by rep_st stateno;  run; 
 
/*get the variables of first cd4 count year and  month    */ 
/*remove the cases if their first cd4 count was obtained 6  after 
aids diagnosis */ 
data two1; 
set two ; by rep_st stateno;  
a= substr(th1yrmo, 1, 2); 
b = substr(th1yrmo, 3, 2); 
if a in ('.', '..') then delete ; 
if b in  ('.', '..') then delete ; 
   th1yr=int(th1yrmo/100); 
  th1mo=mod(th1yrmo,100);  
if a= 0  then do  _th1yr= 2000 + th1yr;   end; *year >= 2000;  
else  do         _th1yr= 1900+ th1yryr;   end; *year>=1996; 
  /* remove cases with missing months of first cd4 count test*/ 
  if th1mo in (0,.) then cd4=.; 
  if  52=<th1yr<=95   then delete;  *dxyr between 1952 and 1995; 
  *if th1yr=6 then delete ;  run; 
 
 
data cases ; 
merge one (in = x ) two1; by   rep_st  stateno; 
if x ;  run; 
 
  /*if the first cd4 count was obtained 6 month after diagnosis, 
take the first   
   cd4 count as missing */ 
data a.cases1; 
 set cases; by rep_st stateno; 
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 if ageaids>=13; 
 if th1yrmo<adxyrmo  then cd4=.; 
 if _th1yr>= dxyr  then do cd4mo =(_th1yr-dxyr)*12 + (th1mo-dxmo);  
end;  
 if cd4mo>6 then do cd4 =.;                       end ;   
 if th1yr in (.,   ..  ) then do cd4 =. ;         end ; 
 if th1mo in ( .,   .. ) then do cd4 =. ;         end;  
  run; 
 
 
 
************************************************* 
/*reclassify the variables */ 
dataset for frequency table  
**************************************************; 
data a.cases2; 
 
options nofmterr; 
set a.cases1; 
race =1*old_race; 
agegrp=0;  
 if 13=<ageaids<=19 then agegrp= 1 ; 
 else if 20=<ageaids<=29 then agegrp= 2 ; 
 else if 30=<ageaids<=39 then agegrp= 3 ; 
 else if 40=<ageaids<=49 then agegrp= 4 ; 
 else if 50=<ageaids<=59 then agegrp= 5 ; 
 else if ageaids>=60 then agegrp= 6 ; 
 
_cd4=0; 
if        0=<cd4 <50    then _cd4 = 1; 
else if  50=<cd4 <=99   then _cd4 = 2; 
else if  100=<cd4 <=199 then _cd4 = 3; 
else if  cd4 >= 200     then _cd4 = 4; 
else                         _cd4 = 5; *frist cd4 count missing;   
 
_virload =0; 
 
     if    virload in (1  2)       then    _virload= 1;  
else if    virload= 3              then    _virload  = 2;  
else if    virload= 4              then    _virload  = 3;  
else if    virload= 5              then    _virload  = 4;  
else if    virload in (6  7  8 )   then    _virload  = 5; *virload 
>6;  
else                                       _virload  = 6; * virlaod 
missing;  
 
/*reclassify the mode value */ 
 
  if mode = 5 then mode = 4; *amode = 5 ; 
  if mode =9 then  mode=5;    *amode = 9; 
 
 
   if mode =1 then mode =1;       
 else if mode =2 and sex = 1 then mode = 2;  
  else if mode = 2 and sex = 2 then mode = 3;  
  else if mode = 3 then mode = 4;  
  else if mode = 5 and sex = 1 then mode = 5;  
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  else if mode = 5 and sex = 2 then mode = 6;  
  else mode=7;  
 
run;  
 
 
/* There were 339863 observations read from the data set A.CASES1. 
NOTE: The data set A.CASES2 has 339863 observations and 75 
variables. 
NOTE: DATA statement used (Total process time):*/ 
 
data a.aids1; set a.cases2; by rep_st stateno;  
race= 1*old_race; 
  k=min(&maxfupyr,1+int((survmo-0.5)/12)); 
  do fu=1 to k; 
     _year=dxyr+fu-1;  
     _age=ageaids+fu-1; 
  if _age>85 then _age=85; 
 
     if fu<k then do; y=1; d=0; w=0; end; else 
  if survmo>36 then do; y=1; d=0; w=1; end; 
  else do; y=max(0.5,survmo-(fu-1)*12)/12; d=1*death; w=1-d; 
end; 
     output; 
  end; 
  keep rep_st stateno dxyr fu _year sex _cd4 _virload race _age 
ageaids survmo  mode y d w; run; 
 
 
proc sort data=a.aids1; by _year sex race _age; run; 
 
 
/*There were 913707 observations read from the data set A.AIDS1. 
NOTE: The data set A.AIDS1 has 913707 observations and 16 
variables.*/ 
 
 
/* import the dataset of population data set containing the 
population mortality in a.popmort  */ 
 
 
  data a.aindivid;  
  merge a.aids1(in=f) a.popmort;  
  by _year sex race _age; 
  if  f; 
  keep rep_st stateno _year sex race _cd4 _virload survmo _age 
ageaids  dxyr fu mode y d w prob;  run; 
 
  proc sort data=a.aindivid; by rep_st stateno fu;  run; 
 
 
  data a.aindivid1; set a.aindivid; 
 
  agegrp=0;  
 if 13=<_age<=19 then agegrp= 1 ; 
 else if 20=<_age<=29 then agegrp= 2 ; 
 else if 30=<_age<=39 then agegrp= 3 ; 
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 else if 40=<_age<=49 then agegrp= 4 ; 
 else if 50=<_age<=59 then agegrp= 5 ; 
 else if _age>=60 then agegrp= 6 ; 
 
length=1; 
  p_star=prob**length; 
  d_star=-log(p_star)*(y/length); 
 
label 
d_star='Expected number of deaths' 
d='Indicator for death during interval' 
w='Indicator for censored during interval' 
y='Person-time (years) at risk during the interval' 
length='Interval length (potential not actual)' 
ln_y='ln(person-time at risk)' 
p_star='Expected survival probability' 
_age='Attained age' 
_year='Attained calendar year' 
range='Life table interval' 
fu='Follow-up interval' 
sex='Sex' 
; 
  keep rep_st stateno _year sex race survmo  _cd4 _virload   agegrp  
dxyr fu mode y d w  
prob length p_star d_star; run; 
 
 
proc freq data =a.aindivid1; 
 
tables _cd4  sex race survmo   _virload mode  agegrp  dxyr fu d ;  
run; 
 
/*add the variable byvar for computation the survival rate of total 
group */ 
data  a.atotal; 
 
options nofmterr; 
set a.aindivid1; 
byvar=1; run; 
 
proc contents data = a.aindivid1; run; 
 
%macro summary (indata, outdata, var  ) ; 
 
proc summary data=&indata  nway; 
var d w p_star y d_star; 
id  length; 
class &var  fu; /* Follow-up must be the last variable in this list 
*/ 
output out=&outdata (drop=_type_ rename=(_freq_=l))  
       sum(d w y d_star)=d w y d_star mean(p_star)=p_star; run; 
 
%mend summary; 
 
%summary(a.aindivid1, race1,     race   ) 
%summary(a.aindivid1, agegrp1,   agegrp ) 
%summary(a.aindivid1, mode1,     mode   ) 
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%summary(a.aindivid1, sex1,      sex    ) 
%summary(a.aindivid1, dxyr1,     dxyr   ) 
%summary(a.aindivid1, _cd41,      _cd4    ) 
%summary(a.aindivid1, _virload1,  _virload) 
%summary(a.atotal,    total1,     byvar   ) 
 
*******************************************************************
**************** 
/*computation  and selection of 1, 3-year cumulative relative 
survival probability*/ 
*******************************************************************
****************; 
 
 
%macro surv(indata,outdata, var, num ); 
data outdata; 
retain cp cp_star cr 1; 
set &indata; 
where fu<=3;  * maximum follow up  to 10 year, which can be changed 
by requirement;    
if fu=1 then do; 
  cp=1; cp_star=1; cr=1; se_temp=0; 
  end; 
l_prime=l-w/2; 
ns=l_prime-d; 
/* Two alternative approaches to estimating interval-specific 
survival */ 
/* Must use the hazard approach for period analysis */ 
p=exp(-(d/y)*length); /* transforming the hazard */  
p=1-d/l_prime; /* actuarial approach */ 
r=p/p_star; 
cp=cp*p; 
cp_star=cp_star*p_star; 
cr=cp/cp_star; 
ln_y_group=log(l_prime-d/2); 
ln_y=log(y); 
d_star_group=l_prime*(1-p_star); 
excess=(d-d_star)/y; 
se_p=sqrt(p*(1-p)/l_prime); 
se_r=se_p/p_star; 
se_temp+d/(l_prime*(l_prime-d)); /* Component of the SE of the 
cumulative survival */ 
se_cp=cp*sqrt(se_temp); 
se_cr=se_cp/cp_star; 
 
/* Calculate confidence intervals on the log-hazard scale and back 
transform */ 
/* First for the interval-specific estimates */ 
if se_p ne 0 then do;   
  /* SE on the log-hazard scale using Taylor series approximation 
*/ 
  se_lh_p=sqrt( se_p**2/(p*log(p))**2 ); 
  /* Confidence limits on the log-hazard scale */ 
  lo_lh_p=log(-log(p))+1.96*se_lh_p; 
  hi_lh_p=log(-log(p))-1.96*se_lh_p; 
  /* Confidence limits on the survival scale (observed survival) */ 
  lo_p=exp(-exp(lo_lh_p)); 
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  hi_p=exp(-exp(hi_lh_p)); 
  /* Confidence limits for the corresponding relative survival rate 
*/ 
  lo_r=lo_p/p_star; 
  hi_r=hi_p/p_star; 
  /* Drop temporary variables */ 
  drop se_lh_p lo_lh_p hi_lh_p; 
  /* Formats and labels */ 
  format lo_p hi_p lo_r hi_r 8.5; 
  label  
  lo_p='Lower 95% CI for P' 
  hi_p='Upper 95% CI for P' 
  lo_r='Lower 95% CI for R' 
  hi_r='Upper 95% CI for R' 
  ;                         end; 
 
/* Now for the cumulative estimates */ 
if se_cp ne 0 then do;   
  /* SE on the log-hazard scale using Taylor series approximation 
*/ 
  se_lh_cp=sqrt( se_cp**2/(cp*log(cp))**2 ); 
  /* Confidence limits on the log-hazard scale */ 
  lo_lh_cp=log(-log(cp))+1.96*se_lh_cp; 
  hi_lh_cp=log(-log(cp))-1.96*se_lh_cp; 
  /* Confidence limits on the survival scale (observed survival) */ 
  lo_cp=exp(-exp(lo_lh_cp)); 
  hi_cp=exp(-exp(hi_lh_cp)); 
  /* Confidence limits for the corresponding relative survival rate 
*/ 
  lo_cr=lo_cp/cp_star; 
  hi_cr=hi_cp/cp_star; 
  /* Drop temporary variables */ 
  drop se_lh_cp lo_lh_cp hi_lh_cp; 
  /* Formats and labels */ 
  format lo_cp hi_cp lo_cr hi_cr 8.5; 
  label  
  lo_cp='Lower 95% CI for CP' 
  hi_cp='Upper 95% CI for CP' 
  lo_cr='Lower 95% CI for CR' 
  hi_cr='Upper 95% CI for CR' 
  ;                                    end; 
 
drop se_temp; 
label 
/* range='Interval' */ 
fu='Interval' 
l='Alive at start' 
l_prime='Effective number at risk' 
ns='Number surviving the interval' 
d='Deaths' 
w='Withdrawals' 
p='Interval-specific observed survival' 
cp='Cumulative observed survival' 
r='Interval-specific relative survival' 
cr='Cumulative relative survival' 
p_star='Interval-specific expected survival' 
cp_star='Cumulative expected survival' 
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ln_y_group='ln(l_prime-d/2)' 
ln_y='ln(person-time) (using exact times)' 
y='Person-time at risk (using exact times)' 
d_star='Expected deaths (using exact times)' 
d_star_group='Expected deaths (approximate)' 
excess='Empirical excess hazard' 
se_p='Standard error of P' 
se_r='Standard error of R' 
se_cp='Standard error of CP' 
se_cr='Standard error of CR' 
; 
format p cp r cr p_star cp_star 5.3; 
run; 
 
proc sort data = outdata; by &var  fu ; run; 
 
data outdata;  
retain r1 cr1 cr3 cr5 cr10 cr20 cir1 cicr1 cicr3 cicr5 cicr10 ; 
length cicr5 $ 12; 
set outdata; 
by &var fu; 
 
if fu=1 then do; r1=.;  cr1=.; cr3=.;  cr5=.; cr10=.;  end; 
if fu=1 then do; r1=r; cir1='('||put(lo_r,4.2)||', 
'||left(put(hi_r,4.2))||')';  
                 cr1=cr; cicr1='('||put(lo_cr,4.2)||', 
'||left(put(hi_cr,4.2))||')';  end; 
if fu=3 then do; r3=r; cir3='('||put(lo_r,4.2)||', 
'||left(put(hi_r,4.2))||')';  
                 cr3=cr; cicr3='('||put(lo_cr,4.2)||', 
'||left(put(hi_cr,4.2))||')';  end; 
 
*if fu=5 then do; *cr5=cr; *cicr5='('||put(lo_cr,4.2)||', 
'||left(put(hi_cr,4.2))||')'; *end; 
*if fu=10 then do; *cr10=cr; *cicr10='('||put(lo_cr,4.2)||', 
'||left(put(hi_cr,4.2))||')'; *end; 
*if fu=20 then do; *cr20=cr; *cicr20='('||put(lo_cr,4.2)||', 
'||left(put(hi_cr,4.2))||')';* end; 
 
 
keep   &var  r1 cir1 cr1 cicr1 r3 cir3 cr3 cicr3;   
 
label 
l_zero='l_zero' 
r1 ='1-year RSR' 
r3='3_year RSR' 
cr1='1-year cum RSR' 
cr3='3-year cum RSR'; 
*cr5='5-year cum RSR' 
*cr10='10-year cum RSR'; 
*cr20='20-year cum RSR'; 
run; 
 
data &outdata; 
 
set outdata ; 
do i = 1 to &num;  
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m=3*i; 
if _n_ = m then  output; 
end;  
 
keep   &var fu r1 cir1 cr1 cicr1 r3 cir3 cr3 cicr3;  run;  
%mend; 
 
%surv(race1,       race2,        race,     5 ); 
%surv(agegrp1,     agegrp2 ,     agegrp,   6 ) 
%surv(mode1,       mode2,        mode,     7 ) 
%surv(sex1,        sex2,         sex,      2 ) 
%surv(dxyr1,       dxyr2,         dxyr,    8 ) 
%surv(_cd41,       _cd42  ,      _cd4,     5 ) 
%surv( _virload1,  _virload2,    _virload, 6 ); 
%surv(total1,      total2,       byvar,    1 ); 
 
 
/*get the frequency for the aids relative survival table  */ 
 
%Macro freq(indata, var1, var2, var3, var4, var5, var6, var7 );  
           %do i=1 %to 7; 
    ods output Freq.table&&i..OneWayFreqs=tab&&i; 
        %end;  
  proc freq  data = &indata; 
     tables   race agegrp mode sex  dxyr _cd4  _virload;    run; 
%Mend freq; 
 
 
%freq (a.cases2, race,  agegrp, mode, sex, dxyr  _cd4  _virload  ) 
 
%macro clean(indata, outdata, var ); 
 
  data &outdata; 
  set &indata (keep = &var frequency percent ); 
  run; 
 
 %mend clean ; 
 
  %clean(tab1, race3,   race ) 
  %clean(tab2, agegrp3, agegrp ) 
  %clean(tab3, mode3,   mode ) 
  %clean(tab4, sex3,   sex ) 
  %clean(tab5, dxyr3,   dxyr ) 
  %clean(tab6, _cd43,  _cd4) 
  %clean(tab7,_virload3, _virload ) 
 
  /*merge the frequency table and the relative survival table 
             for each variables */ 
 
%macro merge(indata1, indata2,  outdata, var  ); 
  data &outdata ; 
  merge &indata1  &indata2; by &var; 
  run; 
%mend; 
 
  %merge (  race3,         race2,       race4,       race    ) 
  %merge (  agegrp3,       agegrp2,     agegrp4 ,    agegrp  ) 
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  %merge (  mode3,         mode2,       mode4,        mode   ) 
  %merge (  sex3,          sex2,        sex4,         sex    ) 
  %merge (  dxyr3,         dxyr2 ,      dxyr4,        dxyr   ) 
  %merge (  _cd43,        _cd42,        _cd44,        _cd4    ) 
  %merge (  _virload3,    _virload2,   _virload4,     _virload ) 
 
 
  /*generate the survival table aids to death dataset */ 
 
The SAS code for  table generation was  omitted.   
 
2. SAS code for table 2 (omitted   is similar to the codes for Table1, the only 
difference is table 2 use HIV to death data     
 
3. SAS codes for relative excess hazard analysis (table3 )   
 
 
1, To obtain the effects of AIDS (table 3 column 2,3 )    
 
libname aids  'c:\xzhang18';  
libname a  'c:\xzhang18\sasdata';  
 
data individ; 
 
options nofmterr; 
set a.individ;  
  run; 
data a.individ; 
set individ; 
ln_y=log(y); 
run; 
  
/**************************************************************** 
Collapse the data to produce the grouped . 
****************************************************************/ 
 
proc summary data=a.individ  nway; 
var d w p_star y d_star; 
id  length; 
class  race  agegrp sex _cd4 _virload mode dxyr fu;/*Follow-up must 
be  
the last variable in this list*/ 
output out=grouped (drop=_type_ rename=(_freq_=l))  
       sum(d w y d_star)=d w y d_star mean(p_star)=p_star; 
run; 
 
data a.grouped; 
 
 
set grouped; run;  
 
 
/**************************************************************** 
Calculate life table quantities.  
****************************************************************/ 
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data a.grouped; 
 
set a.grouped; 
 
l_prime=l-w/2; 
ns=l_prime-d; 
/* Two alternative approaches to estimating interval-specific 
survival */ 
/* Must use the hazard approach for period analysis */ 
p=exp(-(d/y)*length); /* transforming the hazard */  
p=1-d/l_prime; /* actuarial approach */ 
 
ln_y_group=log(l_prime-d/2); 
ln_y=log(y); 
d_star_group=l_prime*(1-p_star); 
excess=(d-d_star)/y; 
 
label 
 
fu='Interval' 
l='Alive at start' 
l_prime='Effective number at risk' 
ns='Number surviving the interval' 
d='Deaths' 
w='Withdrawals' 
p='Interval-specific observed survival' 
 
p_star='Interval-specific expected survival' 
 
ln_y_group='ln(l_prime-d/2)' 
ln_y='ln(person-time) (using exact times)' 
y='Person-time at risk (using exact times)' 
d_star='Expected deaths (using exact times)' 
d_star_group='Expected deaths (approximate)' 
excess='Empirical excess hazard' 
; 
run; 
 
 
 
data grouped2; 
 
set a.grouped(obs= 20000) ; 
run; 
 
 
proc freq data = a.grouped ;  
tables fu sex race _cd4 _virload mode agegrp dxyr ;  run;  
 
  
ods output parameterestimates=parmest /* parameter estimates */ 
           modelinfo=modelinfo        /* Model information */ 
           modelfit=modelfit          /* Model fit information */ 
           convergencestatus=converge /* Whether the model 
converged */ 
           type3=type3estimates;      /* Type III estimates */ 
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proc genmod data=a.grouped ; 
title 'Poisson error model fitted to collapsed data (based on exact 
survival times)  [model 4] '; 
fwdlink link = log(_MEAN_-d_star); 
invlink ilink= exp(_XBETA_)+d_star; 
class sex agegrp race mode dxyr _cd4 _virload fu /param= ref  
ref=first order= internal ; 
model d = fu sex agegrp race mode dxyr _cd4 _virload  
fu*sex  fu*agegrp  fu*race   fu*mode  fu*dxyr  fu*_cd4  fu*_virload  
sex*agegrp  sex*race sex*dxyr  sex*_cd4 sex*_virload 
agegrp*race agegrp*mode agegrp*dxyr agegrp*_cd4 agegrp*_virload   
mode*dxyr mode*_cd4 mode*_virload 
dxyr*_cd4 dxyr*_virload 
_cd4*_virload /error=poisson offset=ln_y type3; 
run; 
 
ods output close; 
 
 
data parmest; 
set parmest; 
if df gt 0 then do; 
rer=exp(estimate); 
low_rer=exp(estimate-1.96*stderr); 
hi_rer=exp(estimate+1.96*stderr); 
end; 
run; 
 
 
proc contents data =   parmest;  run;  
 
 
proc contents data= parmest;   run; 
 
 
data aidspar; 
set parmest; 
if parameter not in ( 'fu',  'intercept',   'scale') ; 
aidsrer =rer; 
cia='('||put(low_rer,4.2)||', '||left(put(hi_rer,4.2))||')';  
keep parameter  aidsrer  CIa; 
format  aidsrer  4.2     ; 
run; 
 
 
2, To obtain the effects of HIV (table 4 column 4,5 )    
 
 
ibname aids  'c:\xzhang18';  
libname a  'c:\xzhang18';  
libname HIV  'G:\hivdata';  
 
data Hindivid; 
set HIV.Hindivid;  
  run; 
 
 proc contents data = hindivid;  run;   
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proc freq data=  hindivid;   
tables     sex race _cd4 _virload  mode dxyr agegrp; 
run;  
/**************************************************************** 
Collapse the data to produce the grouped . 
****************************************************************/ 
 
proc summary data=Hindivid  nway; 
var d w p_star y d_star; 
id  length; 
class  race  agegrp sex _cd4 _virload mode dxyr fu;/*Follow-up must 
be  
the last variable in this list*/ 
output out=grouped (drop=_type_ rename=(_freq_=l))  
       sum(d w y d_star)=d w y d_star mean(p_star)=p_star; 
run; 
 
data HIV.grouped; 
 
 
set grouped; run;  
 
 
/**************************************************************** 
Calculate life table quantities.  
****************************************************************/ 
data grouped; 
 
set HIV.grouped; 
 
l_prime=l-w/2; 
ns=l_prime-d; 
/* Two alternative approaches to estimating interval-specific 
survival */ 
/* Must use the hazard approach for period analysis */ 
p=exp(-(d/y)*length); /* transforming the hazard */  
p=1-d/l_prime; /* actuarial approach */ 
 
ln_y_group=log(l_prime-d/2); 
ln_y=log(y); 
d_star_group=l_prime*(1-p_star); 
excess=(d-d_star)/y; 
 
label 
 
fu='Interval' 
l='Alive at start' 
l_prime='Effective number at risk' 
ns='Number surviving the interval' 
d='Deaths' 
w='Withdrawals' 
p='Interval-specific observed survival' 
 
p_star='Interval-specific expected survival' 
 
ln_y_group='ln(l_prime-d/2)' 
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ln_y='ln(person-time) (using exact times)' 
y='Person-time at risk (using exact times)' 
d_star='Expected deaths (using exact times)' 
d_star_group='Expected deaths (approximate)' 
excess='Empirical excess hazard' 
; 
run; 
 
proc freq data = grouped ;  
tables fu sex race _cd4 _virload mode agegrp dxyr ;  run;  
 
  
ods output parameterestimates=parmest /* parameter estimates */ 
           modelinfo=modelinfo        /* Model information */ 
           modelfit=modelfit          /* Model fit information */ 
           convergencestatus=converge /* Whether the model 
converged */ 
           type3=type3estimates;      /* Type III estimates */ 
 
proc genmod data=grouped ; 
title 'Poisson error model fitted to collapsed data (based on exact 
survival times)  [model 4] '; 
fwdlink link = log(_MEAN_-d_star); 
invlink ilink= exp(_XBETA_)+d_star; 
class sex agegrp race mode dxyr _cd4 _virload fu /param= ref  
ref=first order= internal ; 
model d = fu sex agegrp race mode dxyr _cd4 _virload    / 
error=poisson offset=ln_y type3; 
run; 
 
ods output close; 
 
 
/*   
 
NOTE: Algorithm converged. 
NOTE: The scale parameter was held fixed. 
NOTE: The data set WORK.TYPE3ESTIMATES has 8 observations and 4 
variables. 
NOTE: The data set WORK.CONVERGE has 1 observations and 2 variables. 
NOTE: The data set WORK.MODELFIT has 5 observations and 4 variables. 
NOTE: The data set WORK.MODELINFO has 7 observations and 6 
variables. 
NOTE: The data set WORK.PARMEST has 36 observations and 9 variables. 
NOTE: PROCEDURE GENMOD used (Total process time): 
      real time           3:52:16.44 
      cpu time            3:51:55.22 
 
*/ 
 
 
data parmest; 
set parmest; 
if df gt 0 then do; 
rer=exp(estimate); 
low_rer=exp(estimate-1.96*stderr); 
hi_rer=exp(estimate+1.96*stderr); 
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end; 
run; 
 
 
proc contents data =   parmest;  run;  
 
 
proc contents data= parmest;   run; 
 
 
data HIV.HIVpar; 
set parmest; 
if parameter not in ( 'fu',  'intercept',   'scale') ; 
HIVrer =rer; 
ciHIV='('||put(low_rer,4.2)||', '||left(put(hi_rer,4.2))||')';  
keep parameter  HIVrer  CIHIV; 
format  HIVrer  4.2     ; 
run; 
 
 
data hiv.modelfit; 
 
set modelfit; run; 
 
data hiv.type3estimates; 
set type3estimates; run; 
 
 
4. SAS codes for Table 4(omitted  ) , the SAS code difference between table1 
and 4 is Table 4 use HIV to AIDS data   
 
 
5. SAS codes for model comparison ( omitted ) 
 
6 S-plus codes  for mean residual life ( from Dr. Qin ) 
 
# S code for EL based CI for MRL at xx  
   
alpha<-0.05     # confidence level 
 
# Please input xx, z and xdelta 
 
xx<-12        # a time point at which the MRL needs to be 
estimated   
#x<-rexp(n=30, rate=1)  # liftime 
#y<- rexp(n=30, rate=0.2)     # censoring time 
 
z<-h1[,3]       # vector of min(x,y), observed time 
n<-length(z) 
xdelta<-h1[,7] 
ydelta<-1-xdelta 
cenp<-mean(ydelta)   # censoring rate 
 
xkm<-survfit(Surv(z, xdelta)~1, type="kaplan-meier") 
xtable<-summary(xkm) 
xt<-xtable$time    # distint death time from x sample  
xtx<-xt[xt>=xx]    # distint death time greater than xx 
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xtx1<-c(xt[xt<xx][length(xt[xt<xx])],xtx[-length(xtx)]) 
Fhat<-xtable$surv    # The K-M estimate for 1-F 
Fhatx<-Fhat[xt>=xx] 
Fhatx1<-c(Fhat[xt<xx][length(Fhat[xt<xx])],Fhatx[-length(Fhatx)]) 
dj<-xtable$n.event   # number of deaths at distint death time 
djx<-dj[xt>=xx]    # number of deaths at death time greater than 
xx 
yj<-xtable$n.risk 
yjx<-yj[xt>=xx] 
cmu<-cumsum(Fhatx1*(xtx-xtx1)) 
meanmu<-cmu[length(cmu)] # meanmu=sum(Fhatx1*(xtx-xtx1)) 
sigmax<-sum( ((meanmu-cmu)^2*djx/(yjx-djx))[yjx>djx] )/((Fhatx1[1])^2) 
        # variance  of \wh M(xx) 
Mhatxx<-meanmu/Fhatx1[1]   
        # Estimate for the MRL at xx, \wh 
S(xx)=Fhatx1[1] 
 
 
# Normal Approx. based CI for M(xx): 
 
lowmx<-Mhatxx- qnorm(1-alpha/2)*(sigmax)^(1/2) 
        # lower limit of the normal approx. based CI 
for M(x) 
uppmx<-Mhatxx+ qnorm(1-alpha/2)*(sigmax)^(1/2) 
        # upper limit of the normal approx. based CI 
for M(x) 
widmx<-uppmx-lowmx    
        # length of normal approximation based CI for 
M(xx) 
 
 
 
 
sink("mrlexamp3eout") 
cat("Sample size=", n, "level=",1-alpha, "xx=", xx, "Estimated Mxx=", 
Mhatxx, "censoring rate=", cenp, "\n")  
cat(" ","\n") 
 
cat("lower limit of the normal approx. based CI for M(x) is:", lowmx, "\n") 
cat("upper limit of the normal approx. based CI for M(x) is:", uppmx, "\n") 
cat("length of the normal approx. CI for M(x) is:", widmx, "\n") 
 
sink() 
 
Mhatxx 
 
Lowmx 
 
uppmax 
